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Abstract  
Towards the development of drug carriers that are capable of crossing the Blood Brain 
Barrier, the techniques of emulsion polymerisation and nanoprecipitation have been 
utilised to produce nanoparticulate carriers from a systematic series of alkylglyceryl 
dextrans (of two different average molecular weights, 6 kDa and 100 kDa) that had been 
functionalised with ethyl and butyl cyanoacrylates. Also, zero length grafting of polylactic 
acid to butyl, octyl and hexadecylglyceryl dextrans has allowed the preparation of 
polylactic acid-functionalised nanoparticles. All materials and derived nanoparticles have 
been characterised by a combination of spectroscopic and analytical techniques. The 
average size of nanoparticles has been found to be in the range 100-500 nm. Tagging or 
loading of the nanoparticles with fluorophores or model drugs allowed the preliminary 
investigation of their capability to act as controlled-release devices. The effects of an 
esterase on the degradation of one such nanoparticulate carrier have been studied. 
Testing against bend3 cells revealed that all materials display dose-dependent 
cytotoxicity profiles, and allowed the selection of nanocarriers that may be potentially 
useful for further testing as therapeutic delivery vehicles for conditions of the brain.   
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1. Introduction and aims  
1.1 Drug delivery to the brain 
In 2010 it was estimated that 38% of the European population suffered from a brain 
disorder as compared with 27% in 2005 (1). These disorders include the 
neurodegenerative diseases (dementia, epilepsy, multiple sclerosis) and mental disorders 
(depression, schizophrenia, panic disorder, drug dependence and insomnia). 
Epidemiological studies have shown that about one third of the world population may 
suffer from some mental disorder at some stage in their lives (2). Schizophrenia, 
depression, epilepsy, dementia, alcohol dependence and other mental, neurological and 
substance-use (MNS) disorders constitute 13% of the global burden of disease, surpassing 
both cardiovascular disease and cancer (3). A recent review has identified several CNS 
(central nervous system) diseases that may be treatable with biological actives if 
appropriate therapeutic delivery systems were to be developed (4).  
 
Figure 1.1: The structure of the brain (5) 
 
The human brain (Figure 1.1) is irrigated by capillaries the total length of which is 
estimated at ca. 644 km; corresponding to surface area available for transport of about 
20 m2 (6), and a thickness of the cerebral endothelial membrane of the order of 0.2-0.3 
µm.  
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One of the major inhibiting factors to the efficient treatment of brain disorders is the lack 
of universally applicable methods for transporting therapeutic agents across the blood-
brain barrier (BBB), which has evolved to separate circulating blood from the brain 
extracellular fluid (BECF) in the central nervous system (CNS) such as to prevent potential 
neurotoxins from reaching the brain (7). 
 
The BBB, which is formed by capillary endothelial cells (ECs) that are connected by tight 
junctions with an extremely high electrical resistivity (> 0.1 Ω m), allows the passive 
diffusion of some gases and that of water and of some lipid soluble molecules, and also 
the selective transport of certain molecules (glucose, amino acids) that are crucial to 
neural function. Consequently, therapeutic approaches to circumvent the BBB without 
altering its integrity are an area of intense activity in drug research and development.  
 
1.1.1 The blood-brain barrier 
The acknowledgement of the existence of the BBB is consequent to the work of Ehrlich, 
Lewandowsky and Goldmann, in the late 1800s and early 1900s, who reported the 
absence of bile acids, ferrocyanide or trypan blue in the brain and spinal cord following 
intravenous administration of each of these agents (8-11). The BBB is a highly specialised 
brain endothelial structure of the fully differentiated neurovascular system (8). It is 
formed from brain capillary endothelial cells (12) and localized at the level of tight 
junctions (TJ) between adjacent cells. It has been described as a multicellular vascular 
structure that isolates the CNS from systemic blood circulation (13), inhibiting the 
transport into the brain of plasma components, red blood cells and leukocytes. Thus the 
BBB is crucial for preservation and regulation of the neural microenvironment; the 
specialised TJs have been described as the core structures responsible for these functions. 
The endothelial cells of the BBB are characterised by extremely low numbers of 
transcytotic vesicles and by a restrictive paracellular diffusion barrier (13, 14). The barrier 
functions by utilising carrier-mediated transport systems to exert a tight control over the 
movement of nutrient molecules, ions, and oxygen, and to protect the brain from toxins 
and  pathogens (13). The barrier restricts the free flow of hydrophilic compounds, small 
proteins and charged molecules but relatively small lipophilic molecules (<600 Da) that 
can form fewer than nine H-bonds are normally capable of permeating the BBB (15, 16). It 
has been argued that some therapeutic agents may reach the brain if  they are capable of 
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becoming associated with  specific transporters and/or receptors at the luminal side of 
endothelial cells (9). 
 
The main anatomical structure of the BBB (Figure 1.2) is the cerebral blood vessel formed 
by the ECs, which is characterised by low concentrations of leukocyte-adhesion molecules 
and consequently is responsible for the limited immune surveillance inherent to the CNS  
(17). There is a body of experimental evidence which suggests that  attempts to 
compromise the integrity of the BBB for the purpose of delivering therapeutic agents to 
the CNS may distort the balance of transport of molecules between the brain and the 
blood, which in turn may lead to aberrant angiogenesis, vessel regression, brain 
hypoperfusion, intracerebral haemorrhage, trauma, neurodegenerative processes, 
inflammatory responses, or vascular disorder; these responses are capable of generating 
toxic metabolites that could affect  synaptic and/or neuronal functions (8, 18, 19, 20). 
 
Figure 1.2: Cellular interplay at the neurovascular unit (capillary level) (13) 
The BBB consists of a body of cell types that include pericytes, astrocytes, endothelial 
cells and microglial cells (21). Brain capillary endothelial cells are characterised by narrow 
tight junction, by low pinocytic activities and by high metabolic activity. They allow little 
paracellular and no transcellular transport of high-molecular-weight molecules (22).  
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Pericytes are important in supporting BBB development since they influence the 
differentiation and maturation of associated endothelial cells. Their interaction with 
endothelial cells induces the formation of tight junctions. In addition, they serve as 
partial foundation for the basement membrane. Also, pericytes play a significant role in 
cytokines production and in antigens presentation, affect end-foot processes, and 
support proper neuronal functions (13).  
 
Astrocytes account for about 90% of the overall brain mass, they are involved in 
regulation of brain homeostasis through K+ buffering, in the regulation of 
neurotransmitter and growth-factor release, and in the regulation of brain immune 
responses. Astrocytes produce Apolipoprotein E (ApoE), a molecule that has been shown 
to be beneficial to brain homeostasis (23) and may be important in drug transport 
through receptor mediated endocytosis (24). 
 
The BBB is part of the Neurovascular Unit NVU, which presents as an elaborate 
interplay of central and peripheral cells (13). It creates the extracellular fluid 
compartment, the content of which is different to that of somatic extracellular fluid since 
it accommodates both Cerebrospinal (CSF) and Interstitial (ISF) fluids. Also, the BBB acts 
as neuroprotector in that potentially damaging xenobiotics and metabolites are 
prevented entry or are removed from the organ through the action of specialised 
transporters (25). 
 
Tight junctions 
TJs are located in the apical part of the paracellular space and contain transmembrane 
proteins (occludin, claudins, and junctional adhesion molecule-1) and cytoplasmic 
proteins (zonula occludens [ZO]-1, -2, -3 and cingulin) that are bound to the actin 
cytoskeleton (10). 
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Figure 1.3: Tight junction(26) 
 
TJs are domains of occluded intercellular clefts that are shaped either in grooves (E-face) 
or in ridges (P-face) (Figure 1.3). The latter face exhibits higher electrical resistance and 
lower permeability than the former. Particles that associate with tight junctions are found 
in both faces (14). TJs serve a key function in the regulation of paracellular permeability 
and in maintaining cell polarity (27). Intermingled with tight junctions are usually found 
Adherens junctions. The paracellular route of drug delivery occurs via the intercellular 
space and is mediated by alterations of the tight junction barrier of epithelial cells. 
 
A number of signal pathways have been associated with tight junction regulation, which 
involves but is not limited to G-proteins, serine, threonine and tyrosine-kinases, extra- 
and intra-cellular calcium levels, cAMP levels, proteases and cytokines (14). 
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Bidirectional transport between brain and systemic circulation 
The transcellular bidirectional transport across the BBB has been categorized into carrier-
mediated transport, ion transport, active efflux transport, receptor-mediated transport, 
and caveolae-mediated transport of interstitial fluid to blood (28). The influx transporters 
(mostly involved in nutrients import) and the efflux transporters (involved in removal of 
metabolites and neurotoxic compounds from brain) both prevent the entry of xenobiotics 
to the brain (29). An example is P-glycoprotein (P-gp; a 170 kDa protein member of the 
ATP-binding cassette transporters), which is located at the luminal membrane of 
endothelial cells. P-glycoprotein has been suggested to serve as an efflux transporter that 
functions as a clearance system for metabolites and neurotoxic compounds produced in 
the brain (28). It has been shown that P-gp is distributed throughout both the luminal and 
abluminal membranes of the endothelium, and in astrocytes and pericytes,  suggesting 
that the pump may be involved in regulating drug transport processes over the entire CNS 
and at both the cellular and subcellular levels (30).  
 
The movement of nutrients to the brain (e.g. hexoses, amino acids and monocarboxylic 
acids, nucleosides, amines and vitamins), which is facilitated by specialised carrier-
mediated transporters, is characterised by a concentration gradient of each nutrient as it 
moves from blood to brain (Figure 1.4). The inflow of nutrients is regulated by the 
metabolic needs of the brain, but is also affected by the availability of nutrients. 
 
Since the brain depends mainly on glucose for its energy needs, Glucose transporter 1 
(GLUT1) is crucial to brain function. The concentration of GLUT1 is higher at the abluminal 
membrane as compared with that of the luminal membrane (29). Consistent with the 
need for demand-regulated influx of glucose into the organ, the distribution of the same 
transporter in the brain is asymmetric. Facilitative amino acid transport systems at the 
BBB (e.g. L1, y+) provide the brain with all the essential amino acids, while sodium-
dependent amino acid transport systems (e.g. A, ASC) allow the movement of non-
essential amino acids. Sodium-dependent excitatory amino acid transporters are 
responsible for the removal from the brain of potentially toxic acidic amino acids. Biotin, 
pantothenic acid and lipoic acid are transported to the brain by means of sodium-
dependent transporter, while others vitamins (B1, B3, B5, and E) are transported by 
specialised carriers.  
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Localised at the abluminal side of the brain, the sodium pump serves the sodium-
potassium (Na+-K+, ATPase; Figure 1.4) exchange in the brain. Also, the Na+-K+-2Cl- co-
transporter, which resides predominantly at the luminal side of the brain, facilitates the 
control of sodium, potassium and chloride ions at the brain endothelium. The intracellular 
pH of the endothelium is regulated by the co-operative actions of the sodium-hydrogen 
exchanger and the chloride-bicarbonate exchanger, while  calcium efflux is mediated by 
the sodium-calcium exchanger (8, 31). 
Monocarboxylate1 (MCT1) is involved in the regulated transport of ketone molecules to 
the brain, which serve as energy sources, as do hexoses (8). The efflux of anionic 
compounds is mediated by multi drug resistance-associated proteins (MRP) transporters, 
which are known to be involved in the organ-specific efflux of molecules (e.g. breast-
cancer-resistance protein, BCRP) and family members of the organic anion transporting 
polypeptide (OATP) and the organic anion transporter (OAT). These transporters have the 
capability to work co-operatively to inhibit penetration of many drugs into the brain and 
to increase their efflux from the brain.  
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Figure 1.4: A simplified atlas of the BBB (8) 
Introduction and aims 
9 
 
 
1.1.2 Strategies for delivering drugs to the brain 
Several strategies have been proposed towards overcoming the BBB-imposed limitations 
to the delivery of some drugs and other actives to the brain. These strategies may be 
categorised into invasive and non-invasive; the former requires specialised expertise, 
which impacts on costs, while the latter may be readily accessible to patients. 
 
1.1.2.1 Invasive approaches 
Due to the limited access of drugs to the brain via the BBB, invasive procedures represent 
the current method of choice for brain-specific therapeutic delivery. Most of these 
methods are characterised by intraventricular drug infusion or by disruption of the BBB; 
procedures that are both time-consuming and highly specialised (32, 33). Implantation of 
a catheter into the ventricular system for the delivery of drugs directly to brain then 
bypassing the BBB has been described as the most common invasive procedure for drug 
delivery to CNS (34). 
1.1.2.2 Use of penetration enhancers 
Several penetration-enhancing approaches have been adopted towards increased 
paracellular transport in brain capillaries. These include the administration of osmotic 
solutions, the use of vasoactive substances, the utilisation of alkylglycerols (35) and the 
application of physical stimuli (9) to induce an enhancement of drug transport across the 
BBB (36). 
Chemical stimuli and tight-junction modulations have been used for opening the BBB to 
deliver anti-tumour agents to the brain. Although not without side effects, Mannitol has 
been claimed to be preferable to Polysorbate 80 and to Bradykinin for this purpose (10). 
The physical opening of TJs by means of electromagnetic radiation has been documented 
(37); electromagnetic pulses have also been claimed to affect key TJ-related proteins, 
including ZO-1, occludin, and claudin-5 (38).  In attempts to open TJs, sodium caprate has 
been utilised as have Claudin modulator (39) and  junction Zonula Occludens toxin, Zot 
(40). 
 
However, disturbance of the BBB as a means for the delivery of therapeutic molecules to 
the CNS is inhibited by the technological complexity of the approach, by risks of tumour 
dissemination, neurotoxicity and by inadequate selectivity (10).  
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1.1.2.3 Prodrugs  
The use of prodrugs represents another means of circumventing the BBB in the delivery 
of actives to the brain (37, 38). This approach involves the chemical transformation of an 
administered drug to generate an active precursor molecule that is capable of traversing 
the target biological membrane, as is exemplified by the relationship between heroin and 
morphine (Figure 1.5):heroin (a diacetyl ester congener of morphine) is capable of 
penetrating the BBB and subsequently becoming metabolised to produce morphine, 
which is a molecule that is not capable of penetrating the BBB (41).  
 
    
Heroin                                                                                         Morphine 
 
Figure 1.5: Structures of heroin and morphine 
 
Amongst other strategies, the co-administration of drugs with P-gp modulators, the 
utilisation of drug-loaded biopolymers, the use of drug-transporting peptides and the 
structural modification of drugs have all been examined as means of overcoming the BBB 
(33), as has nasal drug delivery (a route that is not impeded by the BBB). 
 
1.1.2.4 Modifications of influx transporters 
The formulation of drugs such that they exhibit structural resemblance to a substrate of  
influx transporters to the brain has been proposed as a strategy towards increased 
availability of a drug to the brain (28). However, an attempted use of a formulation of a D-
glucose-chlorambucil derivative failed to transport this active to the brain consequent to 
the associated inhibition of the GLUT1 influx pump (42). 
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1.1.2.5 Passive drug targeting 
Passive targeting occurs due to extravasation of the nanoparticles at the diseased site 
where the microvasculature is often described as leaky (43).The molecular design of 
nanoparticulate therapeutic vehicles is primarily determined by the need to overcome 
the natural defence mechanisms mononuclear phagocyte system (MPS) that work 
towards their elimination from circulation (43). Selective accumulation of nanocarriers 
and drug then occurs by the enhanced permeability and retention (EPR) effect, The EPR 
effect will be optimal if nanocarriers can evade immune surveillance and circulate for a 
long period (44). 
1.1.2.6 Active drug targeting 
It has been suggested that epitopes or receptors that are overexpressed in certain 
diseased states may be exploited in active drug targeting: if ligands are attached at the 
surface of the nanocarrier for binding to specified receptors expressed at the target site, 
targeted receptors may be expressed homogeneously on all targeted cells. Targeting 
ligands are either monoclonal antibodies (mAbs) and antibody fragments or nonantibody 
ligands. The binding affinity of the ligands influences the tumour penetration because of 
the binding-site barrier. The ligand is selected to bind to a receptor that is overexpressed 
by tumour cells or by tumour vasculature and not expressed by normal cells. The active 
targeting is particularly attractive for the intracellular delivery of macromolecular drugs, 
such as DNA, siRNA and proteins (44). 
 
1.1.2.7 Carrier-mediated delivery (Colloidal drug delivery systems) 
Commonly used nanocarriers for preclinical and clinical drug delivery studies include 
liposomes (e.g. lipodox), dendrimers (Figure 1.6) and solid-lipid nanoparticles, since these 
often combine effective drug delivery with high drug loading capacity (44). 
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Figure 1.6: Types of drug delivery systems (45) 
 
 
Liposomes and micelles 
Although the subject of considerable research efforts, liposome-mediated drug delivery is 
often limited by: the inherent instability of liposomal dispersions, drug leakage, low 
activity due to no specific tumour targeting, nonspecific clearance by the mononuclear 
phagocytic system (MPS) and complications associated with the available large-scale 
production methods (46). Nonetheless, liposome-loaded Doxorubicin (lipodox) has been 
shown to be significantly more effective on resistant cell line than free Doxorubicin.  Co-
administration of Doxorubicin and P-gp inhibitor indicated the capability of the liposomal 
formulation to inhibit the efflux pump P-gp (47-49). Benefits to drug-delivery applications 
have been shown by micellar formulations, as is exemplified by the capability of micelles 
poly caprolactone-b-poly ethylene oxide (PCL-b-PEO) of Doxorubicin to shift the 
accumulation of this active from the cytoplasm to the nucleus, thereby enhancing 
efficacy. 
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In terms of structure, liposomes are small vehicles with an aqueous inner core which may 
be enclosed by unilamellar or multilamellar phospholipid bilayers (50). Polymeric micelles 
(Figure 1.7) are nanocarriers composed of amphiphilic multi-block copolymers capable of 
forming a shell structure (50). 
 
  
 
  Figure 1.7:  Schematic representation of liposomes and micelles (50). 
 
Solid lipid nanoparticles 
Solid lipid nanoparticles (SLN) are particles made from solid lipids and stabilised by 
surfactants. The need for the use of SLNs in drug delivery arises from the inability of 
highly ordered crystal lattices to accommodate large amounts of drug molecules.  With 
reference to parenteral application, SLNs offer physical stability, protection of 
incorporated labile drugs from degradation, controlled drug release (fast or sustained, 
depending on the adopted molecular design), good tolerability and the potential for site-
specific targeting. However SLN structures often suffer from sub-therapeutic loading 
capacity, polymorphic transitions during storage that lead to the expulsion of the active 
and relatively high water content in dispersions (70–99.9%); the removal of excess water 
from SLN dispersions tends to impact upon particle size. Also, the formulation of SLNs 
normally necessitates the use of high concentrations of surfactants and co-surfactants 
(e.g. butanol), which in turn may be undesirable for regulatory purposes. Dependent 
upon the drug/lipid ratio and solubility, the therapeutic content of SLNs may be 
preferentially localised at the core of the particles or at the shell or be molecularly 
dispersed throughout the matrix. The release profile of SLNs may be influenced by 
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chemical modifications at the lipid matrix, by the concentration of co-formulated 
surfactant and by the physical parameters adopted during formulation. For therapeutic 
applications, SLNs are normally injected (intravenously, intramuscularly, subcutaneously 
or directly to the target organ). SLN formulations are suitable for therapeutic uses 
requiring systemic body distribution since their small size minimises the risk of embolism 
by blood clotting or particle aggregation. If administered subcutaneously or designed to 
accumulate in the MPS,  SLNs offer the opportunity to act as a sustained release depot of 
the drug which allows the incorporated drug to be released over extended time scales 
either by the erosion of the SLN matrix (e.g. by means of enzymic degradation) or by 
diffusion from the particles (46). 
  
Dendrimers  
Dendrimer (Figure 1.8) nanocomposites  are symmetric hyper-branched, star-shaped 
structures that are designed such as to produce monodispersed formulations (51). The 
repetitious nature of chain and branching afford a series of radially concentric layers with 
increasing crowding, as is exemplified by poly(amidoamine)-based structures. The 
classification of dendrimers according to generation reflects the exponential increase in 
the number of branches in each layer: dendrimer growth is typically ca. 1 nm per 
generation. Since dendrimers are typically symmetric around the core, their extended 
forms in aqueous media are of spheroidal morphology. The loosely packed core and 
tightly packed periphery of dendrimers often affords good drug loading capacity (52, 53) 
but this is counterbalanced by little control over the release mechanism of loaded drugs. 
Also, because of their branched nature, dendrimers are often amenable to conjugation 
with pharmaceutically active moieties through functional groups. Notably, studies in 
cultured cells (colon carcinoma) have shown that Dox-dendrimers are less toxic than free 
Dox (54).  
 
As compared with linear polymers, dendritic structures have “dendritic voids” that give 
these molecules important and useful features. Dendrimers with a high surface charge 
density due to ionisable groups are amenable to non-stoichiometric association with 
therapeutic molecules through electrostatic interactions. Such dendrimer-drug 
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interactions may afford to actives enhanced solubility, increased stability and efficient 
transport through biological membranes (55).  
 
Figure 1.8: The structure of dendrimer(55) 
Nanoparticulates 
Since colloidal carriers, particularly biodegradable polymeric nanoparticles, are often 
amenable to structural modifications that may bestow to them the capability to be 
transportable through the BBB, many researchers regard these structures as promising 
vehicles for the delivery of drugs to the brain. Many colloid-forming biopolymers (e.g. 
dextran, PACA, PLA) have been considered for the purpose. The properties of 
nanoparticles utilised for the in vivo transport and enhanced pharmacokinetic profile of 
therapeutic compounds originate from their nano-scale size which furnishes them with 
colloidal stability and allows them to penetrate tissues easily through capillaries and 
epithelial linings. Amenability to functionalisation, both at the surface and at the core of 
nanoparticles, has provided opportunities for applications in  drug delivery and in 
molecular imaging (56). The performance of drug-loaded nanocarriers for targeting 
organs or tissues may be fine-tuned by adjusting the balance between particle size, size 
distribution, surface charge, surface modification and hydrophobicity (57).  
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Nanoparticulate drug carriers are nanoscaled solid colloidal structures (nanospheres or 
nanocapsules) that may be prepared from natural or from synthetic polymers (58-60). 
Research efforts in nanoparticle-mediated drug delivery have been rationalised in terms 
of their potential to effect: (i) long blood circulation time that is coupled with a capability 
to enter the smallest capillaries; (ii) resistance to rapid phagocytic clearance; (iii) 
capability to reach the target organ by penetrating cells and tissues; (iv) capacity to 
exhibit controlled release properties that are inherent to the rate of biodegradability or 
occur in response to a stimulus or a combination of stimuli (pH, temperature, ion 
sensibility); and, (v) improved target-organ specificity (61). 
 
For potential use in drug delivery nanoparticles must possess properties of 
biocompatibility and biodegradability to non-toxic and non-immunogenic products (62). 
Nanoparticles are differentiated from larger size congeners by their active surface area 
which in turn impacts upon aspects of chemical and biological reactivity (63) through 
effects at the solid–liquid interface and those at the contact zone with biological 
substrates (64). Chemical composition, surface function, geometry, porosity, surface 
crystallinity, size range, heterogeneity, roughness, and degree of hydrophilicity are all 
considered important in determining the scope and extent of the interactions of 
nanoparticles with biological systems (65). Of importance are the characteristics of the 
surface layer (zeta charge, aggregation potential, dispersion state, stability, extent of 
hydration) as influenced by the characteristics of the surrounding medium (ionic strength, 
pH, temperature, and presence of organic molecules or surfactants) (66). The surface 
chemistry of  nanoparticles that are amenable to functionalisation offers the possibility to 
optimise the behaviour of nanoparticles in biological environments (64). It has been 
suggested that to be usefully applied in drug delivery to the brain (67), nanoparticles 
must have the following characteristics: diameter around 100 nm, physical stability in 
blood (no aggregation), non-susceptibility to the mononuclear phagocytic system (MPS), 
prolonged blood residence time, capacity for BBB-targeted brain delivery (receptor-
mediated transcytosis across brain capillary endothelial cells), amenability to a scalable 
and cost-effective manufacturing process, capacity to accommodate therapeutic agents 
(small molecules, peptides, proteins, nucleic acids), chemical inertness (chemical 
degradation/alteration, protein denaturation), and possible modulation of the drug 
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release profiles. There is experimental evidence to suggest that the size of NP for 
effective brain drug delivery must be in the range 100-300 nm (68). 
Dependent upon their method of formulation and constituent materials, nanoparticles 
formulations may be divided into two broad types, namely: nanospheres and 
nanocapsules. The method of choice for the formulation of nanoparticles of either type is 
interfacial polymerisation (the mixing of an organic phase with an aqueous phase).  
Differences in the two types of nanoparticle are manifested by their morphology and 
architecture and also by the patterns characterising the drug distribution profile and the 
rate of drug release. Drug molecules are localised at the central core of nanocapsules 
whereas in nanospheres they are dispersed evenly throughout the matrix (Figure 1.9). 
Nanocapsules offer the possibility for zero order release while nanospheres normally 
exhibit first order release kinetics (69).  
 
Figure 1.9: Schematic representation of the structure of nanospheres and nanocapsules for drug delivery (50). 
 
1.1.3 Nanoformulated drugs currently in clinical trials  
Amongst the first nanoformulated (Table 1.1) drugs to be employed in CNS-targeted 
clinical trials were glutathione-decorated liposomes, drug-protein conjugates (e.g. 
ANG1005) and polyglutamate paclitaxel (70). The initial promise of these formulations has 
stimulated considerable research activities in the use of nanoparticles as drug carriers, 
with polyester-based structures finding particular favour amongst researchers because of 
their molecular-design-determined biocompatibility and tuneable degradation properties 
(71).  
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Table 1.1 Representative examples of  water- insoluble-drug nanoformulations that are approved for clinical use or 
are under clinical evaluation (72). 
 
 
1.2 Polymeric drug delivery systems  
Owing to their tuneable biodegradability, many polymers, especially polyesters, have 
found applications in drug delivery and in tissue engineering. The archetypal example of 
such a polymer  is polycaprolactone, a biocompatible  and biodegradable polyester (73). 
(Polyesters are synthetic materials that are normally prepared through the 
polycondensation of monomers containing two or more carboxylic acid groups with 
monomers containing two or more hydroxyl functionalities or by the ring-opening 
transesterification of lactones). The biodegradability of polyesters is the result of their 
limited hydrolytic stability which over time results in depolymerisation to the precursor 
monomers. Linked to the hydrolytic depolymerisation of esters is their biocompatibility 
which can be designed into the molecular structure by the appropriate choice of the 
alcohol- and carboxylic acid-functionalised monomers or co-monomers that condense to 
form the macromolecular backbone.  
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The polymeric carriers used in drug delivery systems may be categorised into natural and 
synthetic. The latter materials may be subdivided into biopersistent and biodegradable 
(Table 1.2) polymers. The former comprise stable materials that maintain their 
physicochemical features in the physiological environment; they are eliminated from the 
body without undergoing metabolism (51) and their therapeutic payloads are released by 
diffusion through the polymeric matrix. By contrast, biodegradable polymers undergo 
metabolic transformation at the physiological environment, which renders the kinetics for 
their release highly sensitive to their biodegradation pathway. As long as biodegradable 
materials are not amenable to biodegradation into cytotoxic products, the use of such 
polymers is considered preferable to that of biopersistent molecules, in that 
biodegradable polymeric materials allow for the complete release of the active (51). 
 
The use of biodegradable polymers in drug delivery avoids issues relating to the fate of 
the body of the depleted drug delivery device. Polymeric nanoparticles are most often 
prepared by poly(D,L-lactide-co-glycolide), polylactic acid, polycaprolactone, poly-alkyl-
cyanoacrylates, chitosan and gelatin (57). The loading of drugs to nanoparticles may 
reduce the side effects inherent in most therapeutic agents (e.g. Doxorubicin-loaded 
nanoparticles have been shown to be less toxic than the free drug), and may afford 
control over the release and biodistribution of the active, increase specificity, prolong 
bioactivity and inhibit opsonisation or rapid elimination from circulation. It has been 
claimed that nanoparticles have the capacity to protect anticancer drugs from 
biotransformation and to delay clearance from the host (74). The thermodynamic stability 
of nanoparticles renders them preferable drug-host structures to liposomes, both in 
terms of stability during storage and in biological fluids where they offer in vivo 
protection from proteases (75). Neha et al. (76) have outlined the following potentially 
useful characteristics of polymeric nanoparticles to applications in drug delivery: 
- in terms of efficiency and effectiveness, they offer a significant improvement over 
traditional oral and intravenous methods of administration; 
- they deliver a high concentration of pharmaceutical agent to the desired location; 
- Tuneable drug-release profiles render polymeric nanoparticles ideal candidate 
vehicles for cancer therapy and for the delivery of vaccines, contraceptives and 
targeted antibiotics; 
Introduction and aims 
20 
 
-  Polymeric nanoparticles can be easily incorporated into other technologies 
related to drug delivery, such as tissue engineering; 
- Readily accessible nanoparticle formulations are often capable of affording 
increased stability to volatile pharmaceutical agents. 
 
Table 1.2 Classification of biodegradable polymers(73) 
 
 
 
1.2.1 Poly(alkyl cyanoacrylate)s 
Alkyl cyanoacrylates (ACA) are low viscosity compounds that are formed by the 
condensation reaction of alkyl cyanoacetates and formaldehyde. The first report of a 
cyanoacrylate dates back to 1949, but the importance of this class of molecules as 
adhesives was not realised until 1959 (77). The physicochemical properties of 
cyanoacrylates are determined by the length of their alkyl side chains. Considering their 
proven biocompatibility following extensive use as medical adhesives, alkyl 
cyanoacrylates have been investigated for their ability to form nanoparticulate vehicles 
for biomedical applications; especially for the delivery of cancer drugs (78) and for the 
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transport of therapeutic agents across the BBB (79). Poly(alkyl cyanoacrylate)s are 
colourless brittle materials that are susceptible to environmental degradation unless 
stabilised by acidic stabilizers (80). The ease of degradation is inversely proportional to 
the length of the alkyl chain (81, 82). Methyl cyanoacrylate, ethyl 2-cyanoacrylate, n-butyl 
2-cyanoacrylate, isobutyl cyanoacrylate, isohexyl cyanoacrylate and octyl cyanoacrylate, 
have all been used in the formulation of nanoparticles (Figure 1.10A).  
           
Figure 1.10: The structures of  alkyl cyanoacrylate (R= methyl, ethyl, butyl, isobutyl, isohexyl, octyl etc.) (A) and  
poly(lactic acid) (B). 
Alkyl cyanoacrylates have found diverse practical applications that include use as 
adhesive products for household repairs and for wound closure (short-chain homologues 
are preferred for use as adhesives; 77, 83), weed control (84) and detection of latent 
fingerprints in crime investigations (85, 86). Alkyl cyanoacrylate monomers are highly 
reactive. They polymerise at room temperature via initiation by nucleophiles 
(environmental moisture) through a mechanism that involves chain propagation by the 
repetitive addition of monomer units to the carbanionic end of the growing chain (87). 
For the longer side-chain homologues, the rate of the polymerisation reaction is sensitive 
to temperature.  The polymerisation reaction is sensitive to pH, with neutral to basic pH 
resulting in the agglomeration of monomers (83).  
 
The pioneering work of Troster et al. (88), who reported that coating poly(methyl 
methacrylate) nanoparticles with Polysorbate 80 increased the accumulation of these 
nanoparticles into the rat brain, prompted much work towards nanoparticulate-assisted 
drug delivery to the brain. Consequently, biocompatible PACA polymers have been 
demonstrated to cross the BBB (89), as is exemplified by Polysorbate 80-coated n-butyl-2-
cyanoacrylate (79, 90-92). The initially proposed endocytotic mechanism of transport of 
these nanoparticles, has however been disputed by Olivier et al. (93) who have argued 
that the mechanism of drug transfer involves the induction of toxicity to the BBB. 
Nonetheless, the mechanism of nanoparticle-mediated drug transport across the BBB is 
generally accepted to involve an initial receptor-mediated endocytosis which is followed 
R
n
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by transcytosis into the brain or by drug release within the endothelial cells (94). The use 
of PBCA nanoparticles that are coated with Polysorbate 80 has received considerable 
attention in drug delivery across the BBB (41).  Significantly,  PBCA nanoparticles that had 
been loaded with Doxorubicin and overlaid with the non-ionic surfactant Polysorbate 80 
are reported to be capable of reaching to the brain intact and of releasing their 
Doxorubicin content following endocytotic uptake by brain blood endothelial cells (91). 
The use of Polysorbate 80 coatings has been rationalised in terms of earlier work by 
Kreuter et al.(92), who, on the basis of electron microscopy and fluorescent studies, had 
suggested that drug-loaded nanoparticles coated with Polysorbate-80 undergo 
phagocytic uptake by brain blood vessel endothelial cells. However, the matter is still 
subject to considerable debate since other findings suggest that the uptake of PBCA 
nanoparticles by the brain is consequent to interaction with the LDL-receptor by 
mimicking the LDL-protein following association with Apolipoprotein E from blood plasma 
(95). 
1.2.2. Poly lactic acid (PLA) 
Poly (lactic acid) (Figure 1.10B), PLA, is amongst the most commonly used biodegradable 
polymers in therapeutic delivery, especially that of vaccines. The main criticism this 
polymer has received relates to the generation of acidic micro environments during 
degradation. PLAs are linear aliphatic thermoplastic polyesters (96) that are commonly 
synthesised from the condensation of α-hydroxy acids. The basic building block for PLA is 
lactic acid. PLA is susceptible to degradation by simple aqueous hydrolysis and undergoes 
thermal degradation above 200°C. The respective glass transition and melt temperatures 
of the material are at 55°C and 175°C (97). Owing to its excellent biocompatibility and 
biodegradability (98), PLA has found uses in drug delivery. PLA has been utilised widely as 
a structural polymer or co-polymer in the preparation of nanoparticles. Its combination 
with glycolic acid to form poly (lactic-co-glycolic acid) (PLGA) is well documented, as is its 
zero-length grafting attachment to modified dextran and also its combination with poly Ԑ-
caprolactone. 
1.2.3. Polysaccharides   
 
Dextran, a hygroscopic polysaccharide, is an odourless and tasteless white amorphous 
powder which is insoluble in ethanol and diethyl ether but gradually soluble in water. The 
constitutional repeat unit of dextran is glucose, which forms linear bonds of α-1,6 
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glycosidic linkages with few branches at the α-1,2, α-1,3 and α-1,4 positions (99, 100). 
Apart from its common use in density centrifugation (to remove vasculature of a given 
homogenate) (70, 101); dextran is a useful matrix material for drug delivery applications 
since it exhibits properties of biocompatibility, degradability and non-immunogenicity 
(102). The same material is often employed as surfactant or as copolymer in 
nanoparticles fabrication, especially those of ACA-based structures (103), where it 
imparts increased hydrophilicity by means of the considerable –OH functionalisation of 
the pyranose ring. Notably, the α-1,6 polyglucose linkages of dextran are not susceptible 
to cleavage by most endogenous cellular glycosidases (104). It is a polysaccharide that is 
present in certain microorganisms, especially bacteria. Dextran, which is primarily utilised 
by microorganisms as a structural support material and as an energy store, is also integral 
to the immune-response mechanisms.  
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Figure 1.11: The chemical structure of dextran. 
Dextran has been used for several decades as a plasma volume expander. This highly 
water soluble substance can be readily attached to drugs either directly or through 
linkers. Studies have shown that both the distribution and the elimination of dextran are 
influenced by the combined effects of molecular weight and surface charge of the 
polymer. The degree of water solubility of dextran decreases with increased branching, as 
has been exemplified by the controllable degrees of hydrophobicity that have been 
obtained through modifications with alkyl glycerols  of systematically varied chain lengths 
(105). An in vitro study involving modified dextran has shown that chemically modified 
dextran exhibits reduced rates of dextranase-induced depolymerisation as compared with 
the unmodified material (105). 
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The use of dextran in such applications has been extended to nanoparticulate 
formulations that could involve co-formulation with alkyl cyanoacrylates. Native dextran 
has been used extensively as a surfactant in the formulation of poly(alkyl cyanoacrylate)s-
containing molecular structures (90, 93, 103, 106). The combined use of these materials 
has been rationalised in terms of the capability of dextran to impart to alkyl 
cyanoacrylates flexural strength and an increased capacity to accommodate a therapeutic 
load for drug delivery applications. However, the observation that PECA-Dex structures 
are susceptible to aggregation and to becoming brittle over time has stimulated further 
research activities towards the development of alternative materials with improved long-
term stability. 
 
Polymeric nanoparticles prepared from alkyl cyanoacrylates and dextran have shown 
promise as carrier vehicles for drug delivery to the brain, as is exemplified by the 
observed  delivery of drugs and peptides across the BBB by means of Polysorbate 80-
coated formulations of PACA and dextran. The capability of the biodegradable PACA 
macromolecules to act as carriers for drugs and fluorophores alike has been integral to 
their utilisation in drug delivery (107). It is common practice to incorporate covalently 
bonded fluorophore end groups into the polymer structure by initiating the 
polymerisation reaction by means of nucleophilic fluorophores (108). Alternatively, the 
fluorescent labelling may be achieved by nanoprecipitation of the preformed polymer 
(109).  
 
Derived from chitin, chitosan is regarded as a nontoxic, biocompatible and biodegradable 
cationic polysaccharide. Chitosan is comprised of β(1,4)-linked 2-acetamido-2-deoxy-β-D-
glucan and 2-amino-2-deoxy-β-D-glucan. The commercial preparation of chitosan is 
through alkaline deacetylation of chitin. Chitosan nanoparticles are prepared mainly by 
the ionic gelation of chitosan through the tripolyphosphate anions method (110, 111). 
Chitosan has been utilised widely in the development of controlled-release drug delivery 
systems (51,112). Interestingly, chitosan nanoparticles have been described as an 
efficient vehicle for the delivery of insulin through the nasal mucosa (113). 
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1.2.4. Polycyanoacrylates 
The chemical stability of PACA has been shown to be sensitive to the nature of the 
initiator and the method employed for the polymerisation, and also by the length of alkyl 
side chains. PACAs are susceptible to biodegradation both at the backbone C―C bond 
(due to the presence of the strongly electron withdrawing cyanate group) and at the ester 
linkage (by hydrolysis). The ease of hydrolytic degradation to the alkyl alcohol and to 
poly(alkyl cyanoacrylic acid) has been observed to decrease with increasing length of the 
side chain. Backbone (C―C) degradation occurs  by the unzipping of the polymer chains in 
a depolymerisation process that produces the precursor monomer (108).  
 
The ease with which ACA monomers undergo polymerisation reactions to form PACA, 
coupled with the biocompatibility of PACA and its biodegradability to innocuous products, 
render this polymer a suitable structural material for the fabrication of drug carrier 
structures (58). Conventionally ACA is polymerised in acidified water using a two phase 
polymerisation process that affords control over particle size has been argued however 
that this slow process and yields a particle size distribution that is broader than that 
which can be obtained with ethanol/water systems (114). The easy accessibility and ready 
availability of ECA renders this monomer the cyanoacrylate of choice for nanoparticle 
formulation for anionic emulsion polymerisation reaction via initiation by the hydroxyl 
group of water or the nucleophilic centre of other initiator molecules such as amines 
(114). The amino group of proteins, has been utilised as an initiating moiety in the 
polymerisation of ECA as exemplified by the reaction with Bovine serum albumin (BSA), 
where the protein molecules are also claimed to serve as stabilizer surfactants (114). 
Adjustment of the pH affords control over the size distribution of PACA nanoparticles 
(115) whereas the hydrophobicity of the same nanoparticles may be tuned by adjusting 
the length of the side chain such that control may be exerted over the capacity of 
nanoparticles to swell in biological fluids (116). Transmission electron microscopy (TEM) 
has shown that PECA nanoparticles are structured as a highly porous but dense polymeric 
matrix with high surface area that facilitates the entrapment of wide range of drug 
molecules (117). Clinical trials of formulations of PACA for drug delivery applications have 
not unmasked any metabolites-related toxic effects of notable significance (118). 
M  
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1.3. Methods for the preparation of nanocarriers  
The variants of the two main methods of choice for the preparation of nanoparticles, 
dispersion of preformed polymer and polymerisation of monomers, have been reviewed 
by Rao and Geckeler (119). Nanoparticles formation by the dispersion of preformed 
polymers may involve solvent evaporation, nanoprecipitation, salting out, dialysis, rapid 
expansion of supercritical solution (RESS) and rapid expansion of supercritical solution 
into liquid solvent (RESOLV). The formation of nanoparticles by the polymerisation of 
monomers may utilise the techniques of micro-emulsion, mini-emulsion, surfactant-free 
emulsion or interfacial polymerisation. The method of nanoparticle preparation is 
determined by the chemical structure of the adopted matrix, which in turn is selected 
according to the requirements  of size and of the proposed use (120).   
Other methods that have been utilised for the preparation of nanoparticles for drug 
delivery include: (i) freezing-induced phase separation (121); (ii) emulsion solvent 
evaporation (122); (iii) single emulsion–solvent evaporation technique, which has been 
claimed to be the best general method of encapsulating hydrophobic molecules into 
nanoparticles; and, (iv) miniemulsion, which has been utilised  for the co-formulation of 
paclitaxel and PBCA (123). 
Bertholon et al. (124) in their studies of redox and anionic emulsion polymerisation of 
nanoparticulate PACA have shown that low (highly acidic) pH leads to the formation of 
higher molecular weight and higher average particle size than corresponding 
nanoparticles  prepared at higher pH. The same group of workers speculated that the 
higher molecular weight polymers formed as a result of the highly acidic pH making fewer 
OH groups available for the initiation of polymerisation.  
           
1.4. Characterisation techniques   
Integral to the characterisation of nanoparticles is the determination of size, 
polydispersity index (PDI), zeta potential, texture morphology and thermal stability. 
Particle size and its distribution influence such key properties as stability in suspension, 
viscosity, surface area, and parking density. For biomedical applications, size also impacts 
on the capability of therapeutic agents-loaded nanoparticles to penetrate deeply into 
tissues through the narrow capillary route and further to penetrate cells; amongst other 
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techniques, the sizes of nanoparticles may be determined by DLS, TEM, NTA, SEM, and 
AFM.  
Zeta potential provides a measure of the stability of nanoparticles in a given medium. 
Zeta potential values above 30 mV (-ve or +ve) are normally considered indicative of good 
colloidal stability as it indicates that the electrostatic repulsion between neighbouring 
nanoparticles is greater than the antagonistic van der Waals forces of attraction, 
preventing  aggregation or precipitation (125); zeta potential may be determined by 
dynamic electrophoretic mobility. The preparation of nanoparticles of narrow size 
distribution, as measured by the PDI, is prerequisite to the reproducible behaviour of 
vehicles intended for systemic use.        
  
1.4.1. Elemental analysis 
The technique used for the determination of elemental C, H, and N and S is based on the 
quantitative “dynamic flash combustion” method (Figure 1.12). The samples are held in a 
tin capsule, placed inside the autosampler drum where they are purged by a continuous 
flow of helium and dropped at pre-set intervals into a vertical quartz tube maintained at 
900°C. When the samples are placed inside the furnace, the helium stream is temporarily 
enriched with pure oxygen, the sample melts and the tin promotes a violent reaction 
(flash combustion); under these conditions even thermally resistant substances are 
oxidised fully. Quantitative combustion is then achieved by passing the mixture of gases 
over a catalyst layer. The mixture of combustion gases is then passed over copper to 
remove the excess oxygen and to reduce the nitrogen oxides to elemental nitrogen. The 
resulting mixture is then directed to the chromatographic column where the individual 
components are separated and eluted with the help of a thermal conductivity detector 
(TCD) whose signal feeds the automatic EAGER300™ workstation as nitrogen, carbon 
dioxide, sulphur dioxide and water. The instrument is calibrated with the analysis of 
standard compounds using the K factors calculation or linear regression method 
incorporated in the EAGER300™ software. 
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Figure 1.12: Schematic representation of an elemental analyser (adapted from analyser’s manual). 
 
 
1.4.2. MALDI-TOF MS 
MALDI-TOF MS, a technique developed by Hillenkamp and Karas in 1988 (126), is widely 
utilised for the mass spectroscopic characterisation of proteins and other 
biomacromolecules (127). 
 
Principles of MALDI 
Unlike conventional mass spectroscopy techniques (electron impact, chemical ionisation), 
in MALDI-TOF MS (Figure 1.13) (a technique normally applied in the characterisation of 
complex molecules) ionised molecules (cationic) or molecular fragments that have the 
same energy travel at different velocities, with the implication that fragments of different 
masses reach the detector at different times; larger ions travel with a lower velocity than 
smaller cations. Since the time of travel depends on charge, mass and kinetic energy of 
the ion, delay extraction (DE) has been shown to be very helpful in improving resolution 
in the application of MALDI-TOF; DE is employed to delay the travel of ions by 150 ns 
from formation, such that most of their excess energy is dissipated, before the 
accelerating voltage is applied. However the resolution benefit of DE decreases with 
samples of increasing molecular weight.  
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Sample preparation 
The sample preparation stage is critical in the quality of the spectrum produced in MALDI-
TOF spectrometry. Amongst the methods of sample preparation, the dried-droplet 
method has become the most widely utilised: a saturated matrix solution is mixed with 
the analyte at the ratio of 5000:1, and an aliquot of about 0.5 µl is placed on the sample 
receptor where is dried under vacuum before ionisation. Other approaches to sample 
preparation include: thin and thick layer (127), fast-vaporisation, electrospray, matrix-
precoated layer, particle-doped (two phase liquid) and chemical-liquid (128) methods. 
 
 
Figure 1.13: Schematic representation  of the MALDI instrument (128). 
 
The advent of MALDI has offered many advantages in the analysis of macromolecules as 
compared with conventional chromatographic techniques. These include the capability to 
determine absolute molecular weight irrespective of macromolecular structure, the ease 
of use (the technique imposes few demands in terms of instrument- and sample-
preparation procedures), and the capability to characterise molecules of <20 kDa (128, 
129). However, the technique is regarded as complementary to chromatographic 
methods since it is not suitable for the study of macromolecules with PDI >1.6 or for the 
analysis of complex mixtures of surfactants.  Most importantly, MALDI is of little 
usefulness in the analysis of macromolecules that do not possess chemical functionalities 
that are capable of stabilising the prerequisite  cationic structure at the gaseous phase 
(128).    
              
Introduction and aims 
30 
 
The vaporisation and ionisation technique is widely used in the characterisation of 
biomolecules by MALDI-TOF. This is a non-destructive technique that vaporises and 
ionises large and small biomolecules without promoting fragmentation (Figure 1.14 ). To 
this end, the sample to be analysed is incoporated first into a matrix (e.g. 2,5 
dihydroxybenzoic acid (130, 131), which is in excess of the analyte and functions by 
absorbing strongly the energy of a laser source thereby facilitating for vaporisation of the 
analyte. In doing this, it also serves as proton donor for the analyte thereby facilitating 
ionisation and subsequent analysis by the detector (linear time-of-flight (TOF) analyzer, 
TOF reflectron or fourier transformed mass analyzer). 
 
Figure 1.14: Non-destructive vaporisation and ionisation of biomolecules by MALDI TOF (126) 
 
The usefulness of mass spectrometry methods in the identification and characterisation 
of unknown compounds is twofold, in that it allows the: 
a. Determination of the molecular mass of the compound under study; mild direct 
ionisation techniques allow the detection of the highest m/z ratio ion which often 
corresponds to an isotopic form of the intact, ionised molecule, while chemical 
ionisation techniques (e.g. ESI, MALDI) typically identify the protonated or 
deprotonated form of the molecule. 
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b. Detection of the functional groups present in the molecule on the basis of specific 
fragment ions and/or fragment ion series present in the mass spectrum, and 
characteristic fragment ions formed by loss of neutral molecules from the intact 
ionised molecule. 
 
Synthesis of the spectral information regarding the molecular ion and the identified 
molecular fragments allows the determination of the structure of the molecule under 
study. 
 
The use of high mass resolution instruments allows the minimisation of issues relating to 
peak broadening and of those due to presence of any interfering or isobaric ions.  The 
technique advantages have been put at low cost, high sensitivity, large mass range and 
recording a whole spectrum in a single acquisition step (132).  
 
1.4.3. Nanoparticle Tracking Analysis (NTA) 
Nanoparticle Tracking Analysis (NTA) was developed by Carr et al; in this technique, 
particles under Brownian motion are recorded by software-guided video designed to 
identify and track the centre of each particle on a frame-by-frame basis (Figure 1.15). The 
image analysis software determines the distance moved by each particle, which in turn 
allows the determination of the corresponding diffusion coefficient. The hydrodynamic 
diameter (d) of particles is calculated (133) by inputting the temperature (T) and viscosity 
( ) of the medium into the Einstein-Stokes equation (k = Boltzmann constant). 
D
kT
d
3
   (eq. 1.1) 
 
Figure 1.15: Schematic representation of the Nanoparticle Tracking Analysis (NTA)(133) 
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1.4.4. Zeta potential determination 
There exist two layers around a particle that is suspended in an electrolytic solution, 
namely: the Stern layer and inner region, where the ions are bound strongly; and the 
outer, diffuse region, where the ions are bound less strongly (Figure 1.16). The net 
surface charge of particles determines the distribution of ions surrounding it, effecting 
the formation of an electrical double layer around each particle. Zeta potential is used to 
determine the magnitude of the interaction between charges in a system, and provides a 
measure of surface charge. Thus, zeta potential is the energy difference that exists at this 
boundary. Colloidal systems with a zeta potential between +30 and -30  are normally 
considered stable (134). 
 
 
Figure 1.16: Schematic representation of particles and surround charges  (134) 
 
1.4.5 TGA   
Thermogravimetric analysis TGA (135) is a method of thermal analysis in which changes in 
the physical and chemical properties of materials are monitored either as a function of 
increasing temperature (at constant heating rate), or as a function of time (at constant 
temperature and/or constant mass loss). TGA is used to study the decomposition and 
thermal stability of materials under specified conditions and to examine the kinetics of 
the physicochemical processes occurring within a sample. The technique is commonly 
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employed to determine heat-induced changes that involve either mass loss or mass gain 
due to decomposition, oxidation or loss of volatiles (such as moisture). Factors that 
influence the nature of the TGA curve (Figure1.17) include sample mass, volume and 
physical form, the shape and nature of the sample holder, the nature and pressure of the 
atmosphere in the sample chamber, and the scanning rate. The principal applications of 
TGA in polymers are the determination of the thermal stability of polymers, 
compositional analysis, and identification of polymers from their decomposition pattern.  
 
Figure 1.17 Representative TGA curve. 
 
1.4.6 SEM   
The SEM is a type of electron microscope that produces images of a sample by scanning it 
with a focused beam of electrons. This complements optical images with the traditional 
microscope in that it offers large depth of field (which allows more of a specimen to be in 
focus at one time), and high resolution.  
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Figure 1.18 Scanning electron microscope (136) 
 
The electron beam scans the surface line by line to produce the image (Figure 1.18); since 
metals are conductive, their samples do not require pre-imaging treatment but non-
metals need treatment that renders them conductive; this may involve coating with gold, 
graphite or other electrically conducting materials in a sputter coater. The sample to be 
coated is fixed on a stub and placed under vacuum. The interaction of electron with the 
sample produces many signals which include secondary electrons (SE), back-scattered 
electrons (BSE), characteristic X-rays, light (cathodoluminescence) (CL), specimen current 
and transmitted electrons. The signals result from interactions of the electron beam with 
atoms at or near the surface of the sample. Secondary electrons and backscattered 
electrons are commonly used for imaging samples.  
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1.5. Aim of the study 
Amongst the approaches towards the delivery of therapeutic agents to the brain without 
compromising the integrity of the BBB, the utilisation of polymeric nanoparticulate drug-
carrier vehicles – the focus of this work – has gained considerable following amongst 
researchers. The objectives of this study are to: 
i) synthesise amphiphilic dextran derivatives through functionalisation with alkyl glycidyl 
ethers;  
ii) use these modified dextrans in combination with alkyl cyanoacrylates (ACA) for the  
preparation of well-defined nanoparticles; 
iii)  study the capability of these nanoparticles to act as carriers for fluorescent-marker 
molecules and for small molecule drugs; and, 
iv)  investigate the biodegradability and the potential toxicity of these nanoparticles, and 
assess any associated interactions for the purpose of  evaluating promise in therapeutic 
applications. 
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2 
2. Chemical modifications of dextran 
 
The chemical modification of dextrans has been rationalised in terms of the capability of 
dextran to impart to alkyl cyanoacrylates flexibility and an increased capacity to 
accommodate a therapeutic load for drug delivery applications. However, the observation 
that PECA-Dex structures are susceptible to aggregation and to becoming brittle over 
time has stimulated further research activities towards the development of alternative 
materials with improved long-term stability. The functionalisation of dextrans with alkyl 
glyceryl moieties represents one of the approaches towards that goal. 
 
2.1 Dextran 
Dextran is an odourless and tasteless hygroscopic white powder that is insoluble in 
ethanol or diethyl ether but dissolves gradually in water. It is a polysaccharide that is 
present in certain microorganisms, especially bacteria. Dextran, which is primarily utilised 
by microorganisms as a structural support material and as an energy store, is also integral 
to the immune-response mechanisms.  
 
The chemical structure of dextran (Figure 2.1) is that of a neutral polysaccharide that has 
glucose as its sole constitutional repeat unit. The glucose moieties form linear bonds at 
the α-1, 6 glycosidic linkages (more than 95% of the chain) with few branches at the α-
1,2, α-1,3 and α-1,4 linkages (99, 100). Owing to its glucose-based structure, dextran is 
characterised by biocompatibility, degradability and non-immunogenic properties which 
render it a useful structural material for biomedical applications (102). The use of dextran 
in such applications has been extended to nanoparticulate formulations that often involve 
co-formulation with alkyl cyanoacrylates (24, 93, 137).  
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Figure 2.1: The chemical structure of dextran 
The –OH functionalities render dextran a molecule that is readily amenable to structural  
modification (138).  Consequently, a number of modified dextrans have been prepared in 
which aromatic rings or aliphatic chains are attached to the molecular structure (139-
144). For example, dextran that had been modified by esterification with benzoic acid and 
valeric acid has been used in protein partitioning (145). In other examples, Rouzes et al. 
(98) utilised hydrophobically modified dextran as a surfactant for the preparation of 
nanoparticles with well-defined surface properties, while Sadtler et al. (146)  reported its 
use in the stabilisation of oil-in-water emulsions. Dextran derivatives with good chemical 
stability at extreme pH environments have been achieved through functionalisation with 
1,2-epoxydodecane (144). The chemical modifications of dextran have been extended to 
attempts to obtain amphiphilic polymers which are capable of forming micellar structures 
that can associate with organic solutes at the hydrophobic domain. Rotureau et al. (141) 
have shown that lipophilic modification of dextran through linkage with aromatic or 
aliphatic hydrocarbons results in macromolecular structures of controlled amphiphilicity. 
The amphiphilic nature of modified dextrans renders these materials suitable 
components for the fabrication of nano-sized structures of well-defined size, as is 
exemplified by the work of Rouzes et al. (147) who utilised such materials in combination 
with PLA to produce  nanomaterials in the 150-200 nm range, and that of others who 
utilised amphiphilic dextrans as surface-modification components of both nano- and 
micro-sized drug delivery systems (147, 148). Native dextran has been used extensively as 
α-1,6
α-1,3
...........
α-1,6
...........
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a surfactant in the preparation of poly(alkyl cyanoacrylate)s-based structures (24, 90, 93, 
103). The combined use of these materials has been rationalised in terms of the capability 
of dextran to impart to alkyl cyanoacrylates flexibility and an increased capacity to 
accommodate a therapeutic load for drug delivery applications. However, the observation 
that PECA-Dex structures are susceptible to aggregation and to becoming brittle over 
time has stimulated further research activities towards the development of alternative 
materials with improved long-term stability. The functionalisation of dextrans with alkyl 
glyceryl moieties represents one of the approaches towards that goal. 
 
2.1.1 Chemical structure of oxiranes for synthesis of alkyl-glyceryl dextrans 
Various chain lengths of oxiranes were used in the modification of dextran, these includes 
butyl glycidyl ether, octyl glycidyl ether, glycidyl lauryl ether, tetradecyl glycidyl ether, and 
hexadecyl glycidyl ether (Figure 2.2) 
 
O O
n
 
Figure 2.2 Chemical structure of alkyl glycidyl ether where n=1, butyl; n=5,octyl; n=9, lauryl; n=11,tetradecyl; n=13 
hexadecyl. 
 
2.2 Materials and instrumentation 
Dextrans from Leuconostoc spp. (MW 6 kDa and 100 kDa), dimethyl sulfoxide (DMSO, 
anhydrous, ≥ 99.9)%), potassium tert-butoxide (t-BuOK; reagent grade > 97 %), butyl 
glycidyl ether, octyl/decyl glycidyl ethers, glycidyl lauryl ether, tetradecyl glycidyl ethers 
and hexadecyl glycidyl ether were all obtained from Sigma-Aldrich UK.  
TGA analysis was carried out with TG 209 F1 Libra (TGA from Netzsch Instruments), with 
temperature ranged from 25 to 500°C, heating at 10K/min. under Nitrogen atmosphere. 
A Büchi Rotovapor (R-200) powered with a Sogevac Saskia PIZ 100 vacuum pump 
equipped with a liquid nitrogen trap was used to remove solvents under reduced 
pressure during the process of modified dextrans purification, Dialysis was performed 
using Visking membrane tubing (Medicell International Ltd, UK) with cut-off either 12-14 
kDa or 3.5 kDa in a discontinuous system (10.0 L deionised water (15.0 mΩ); exchanged 3 
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times/day). The alkylglyceryl derived dextrans were characterised by 1H- and 13C-NMR 
spectroscopy using a JEOL Eclipse 400+ instrument (JEOL, UK; 400 MHz for 1H- and 100 
MHz for 13C-NMR); samples were dissolved in either D2O or DMSO-d6 employing 0.2 % 
tetramethylsilane (TMS) as a reference. The spectra were processed using the JEOL Delta 
v 5.0.2 software or Advanced Chemistry Development (ACD) software. FT-IR spectra were 
recorded using a Nicolet 6700 instrument (Thermo Scientific, UK) equipped with an ATR 
Smart Orbit accessory with diamond crystal, at 64 scans and 4 cm-1 data spacing. The 
analysis of spectra was performed using the Omnic Specta 8.0 software; for the FTIR 
analysis, dried samples were used, and analysed by placing the sample on top of the 
diamond crystal plate and reading taken with the Omnic Specta 8.0 software. The 
molecular weights of alkylglyceryl dextrans were estimated using a GPC (waters 2000) 
with a refractive index detector, under thermostatted conditions (temperature 30°C), 
80/20 solution of water/methanol was used as eluent at a flow rate of 0.6 mL/min). The 
calibration was performed with Pullulan standards (Shodex Denko) of MW 0.6 × 104, 1 × 
104, 2.17 × 104, 4.88 × 104 and 11.3 × 104, 21 × 104, 36.6 × 104, 80.5 × 104 g/mol. 
 
MALDI-TOF MS experiments were performed on a Micromass MALDI MicroMX 
instrument operating in positive reflectron mode in the m/z range of 400-1600; a 337nm 
nitrogen laser used for ionisation (pulse setting 1800V; detector setting 2300V; flight tube 
12Kv; reflectron 5.2Kv). α-Cyano-4-hydroxycinnamic acid (CHCA) solution at a 
concentration of 10 mg/mL in acetonitrile:water (50:50) provided the matrix for the 
experiment. CHCA was mixed in the 1:1 ratio with the sample (dissolved in 50:50 v/v 
acetonitrile:water) and deposited onto the MALDI plate. 
 
2.3 Methods  
Dextran (2g; 12.35 mmol), dissolved in anhydrous DMSO (150 mL) , was allowed to stir 
under nitrogen for 2 h before gradual addition of potassium tert-butoxide (t-BuOK) (1.385 
g; 12.35 mmol) that had been dissolved in anhydrous DMSO (50 mL) (t-BuOK was 
dissolved in DMSO by allowing it to stir for 30 min in anhydrous DMSO under Nitrogen 
atmosphere at room temperature).  Stirring was continued for another 2 h before the 
gradual addition of a solution of specified alkyl glycidyl ether (G4, G8, G12, G14, G16) at 
40°C and further stirring for 24 h. After this time, the reaction mixture was transferred 
into a dialyzing membrane vessel (MWCO 3.5 or 12-14 kDa) and dialysed against 
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deionised water (10.0 L; exchanged 3x per day) over five days. The content of the dialysis 
vessel (ca. 400 mL) was washed with diethyl ether or with DCM (3× 150 mL) to remove 
impurities and any unreacted ether. Traces of volatile solvents were removed using the  
rotary evaporator (reduced pressure, 50°C) and the sample was again subjected to the 
dialysis procedure (48 h) before lyophilisation with a Virtis freeze dryer (<-85°C, for 48h) 
to yield the corresponding alkylglyceryl dextrans, which were characterised using FTIR, 
1H- and 13C-NMR spectroscopy, GPC, MALDI-TOF MS, SEM and TGA. Yields were in the 
range 40-60%.  
 
2.4 Results and Discussion 
2.4.1 Synthesis of alkylglyceryl dextrans 
The modification of dextrans with alkyl glycidyl ethers (Figure 2.3) was carried out by 
attaching alkylglyceryl side chains to the hydroxyl groups through two-step reactions 
which involved the conversion of the hydroxyl groups of the pyranose rings of dextran 
into the more reactive alcoholates and subsequent reaction with specified alkyl glycidyl 
ethers (149). The synthesis was carried out, at 40°C, in anhydrous DMSO and under a 
nitrogen atmosphere for 24 h; similar modification of dextran are well documented in the 
literature (139, 141, 144, 150). The reactivity of the –OH pyranose ring of the glucose unit 
is in the order 2>4>3.  
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Figure 2.3: Scheme for the synthesis of alkylglyceryl dextrans 
 
Native dextrans with a molecular weight of either 6 kDa or 100 kDa were modified by 
covalent attachment of alkylglyceryl pendent chains to their hydroxyl groups. This was 
carried out by means of a series of commercially available alkyl glycidyl ethers of different 
chain lengths: butyl glycidyl ether (G4; 1H NMR, 13C-NMR; Appendix 1), octyl glycidyl ether 
(G8), glycidyl lauryl ether (G12), tetradecyl glycidyl ether (G14; 1H-NMR, 13C-NMR; 
Appendix 2), and hexadecyl glycidyl ether (G16; 1H-NMR, 13C-NMR; Appendix 3). The 
reactions produced a range of alkylglyceryl dextrans: butylglyceryl dextrans (Dex100G4 or 
Dex6G4), octylglyceryl dextrans (Dex100G8 or Dex6G8), laurylglyceryl dextrans 
(Dex100G12 or Dex6G12), tetradecylglyceryl dextrans (Dex6G14 or Dex100G14) and 
hexadecylglyceryl dextrans (Dex100G16 or Dex6G16); the numbers 6 and 100 represent 
the molecular weight of the dextrans while 4, 8, 12, 14, 16 represent the chain lengths of 
alkyl glycidyl ethers used for the modification of dextrans. 
Hexadecyl glyceryl dextran was prepared in two-step reactions which involved conversion 
of OH group to more reactive alcoholate with t-BuOK and subsequent reaction with the 
specified glycidyl ether; other dextran derivatives were synthesised through the same 
procedure. 
 
t-BuOKN2 atm. 24 h.
m=3;  G4
m=7;  G8
m=11; G12
m=13; G14
m=15; G16
m=3;   DexG4
m=7;   DexG8
m=11; DexG12
m=13; DexG14
m=15; DexG16
m
R = H or m
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2.4.2 Characterisation of the alkylglyceryl dextrans 
2.4.2.1 NMR and FTIR 
The modified dextran structures were confirmed by FTIR and NMR spectroscopy. The 
modification of the dextran was assessed by comparing the 1H-NMR spectrum of the 
modified dextrans (examples in Figures 2.4 and 2.5) with that of the native material 
(Figure 2.6): the presence of resonances at 0.87 ppm, 1.3 ppm and 1.4 ppm confirmed the 
successful functionalisation of dextran. Similar results were obtained for butyl, octyl, 
lauryl and tetradecyl dextrans. Table 2.1 summarises the DS% of the modified dextrans. 
The successful synthesis of alkylglyceryl dextran was consistent with FTIR spectroscopy 
data: the grafting of alkyl glyceryl chains resulted in the formation of a new secondary 
alcohol. The band at 1012 cm−1 is assigned to the vibrational mode of C –O. In crystalline 
dextran, two absorption peaks at 851 and at 914 cm−1 were observed, respectively 
assigned to (C–C) and (C–H) bending modes. It has been proposed that the absorption 
bands in the spectral range between 1200 and 1500 cm−1 are mainly due to CH 
deformation vibrations and (COH) bending vibrations (151). The bands at 2921 cm-1 and 
at 3215 cm-1 are respectively consistent with (C–H) and (O–H) stretching vibrations 
(Figure 2.7 and Figure 2.8). 
SEM images of native dextran and of Dex100G4 visualised the morphology of these 
materials (Appendix 13). 
 
The enumeration of the degree of substitution (Table 2.1), as expressed by the 
percentage of substituted saccharide units carrying an alkylglycerol group, was achieved 
by 1H-NMR through the comparison of the ratio of integral of the intensity of the terminal 
methyl group of alkyl glycerol (IA) with that of the anomeric proton of the glucopyranose 
ring (IB); (equation 2.1; Table 2.1). 
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Figure 2.4: 
1
H-NMR spectrum of alkyl glyceryl dextran (Dex100G16) 
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Figure 2.5: 
1
H-NMR spectrum of butyl alkyl glyceryl dextran (Dex100G4) 
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Figure 2.6: 
1
H-NMR of native dextran 
 
100*
3
%
B
A
I
I
DS  )    (eq. 2.1) 
 
Table 2.1: The degree of substitution of the synthesised glyceryl dextrans. 
 
 
 
 
 
 
 
 
DexnGm DS (%) 
 Dex6G4 87.70 
 Dex100G4 68.49 
 Dex6G8 114.94 
Dex100G8 64.91 
 Dex6G12 54.35 
Dex100G12 67.56 
Dex6G16 55.56 
Dex100G16 144.92 
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Figure 2.7: FTIR of butyl glyceryl dextran (Dex100G4) 
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Figure 2.8: FTIR of octyl glyceryl dextran (Dex100G8) 
 
2.4.2 GPC 
GPC was used to determine the molecular weight distribution profile of some of the 
synthesised alkylglyceryl dextrans and that of the starting material (native dextrans, Dex 6 
kDa and Dex 100 kDa). Owing to differences in the experimental protocol, the average 
molecular weights of commercial dextrans that served as starting materials were higher 
than those given by the manufacturer (Table 2.4). It was found that Dex6G4 had an 
average molecular weight that was lower than that of the native precursor dextran 
(Dex6), while Dex100G16 had an average molecular weight that was higher than that of 
its precursor macromolecule (Dex100). Since longer chain length should influence the 
GPC-determined average molecular weight, a study was conducted to compare 
Dex100G16 with its progenitor molecule, Dex100, (Table 2.4). The calibration curve of 
pullulan standard, calibration data and the equation of the calibration curve are 
respectively presented in Figure 2.9, Table 2.2 and Table 2.3, while the chromatograms of 
the analysed dextran and alkylglyceryl dextran are reproduced in Figures 2.10-2.13. 
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Figure 2.9 GPC calibration curve (Pullulan standards) 
 
Table 2.2: GPC calibration data using Pullulan standards 
 Retention 
Time /min 
Elution 
Volume 
/mL 
Mol Wt Log (Mol Wt) Calculated 
Weight 
% 
Residual 
Standard 
Type 
Relative 
Weight 
1 9.549 9.549 805000 5.905796 790018 1.896 Narrow 1.00 
2 10.413 10.413 366000 5.563481 383256 -4.502 Narrow 1.00 
3 11.281 11.281 210000 5.322219 206578 1.657 Narrow 1.00 
4 12.219 12.219 113000 5.053078 109750 2.961 Narrow 1.00 
5 13.295 13.295 48800 4.688420 49454 -1.322 Narrow 1.00 
6 14.188 14.188 21700 4.336460 21831 -0.602 Narrow 1.00 
7 14.865 14.865 10000 4.000000 10136 -1.338 Narrow 1.00 
8 15.271 15.271 6000 3.778151 5914 1.459 Narrow 1.00 
 
Table 2.3: Equation calculated for the GPC calibration curve 
 R R^2 Standard Error Equation 
1 0.999902 0.999804 1.407507e-002 Log Mol Wt = 2.24e+001 - 3.87e+000 T^1 + 3.08e-001 T^2 - 8.84e-
003 T^3 
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Figure 2.10 GPC chromatogram of native dextran (Dex6) 
 
 
Figure 2.11: GPC chromatogram of native dextran (Dex100) 
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Figure 2.12: GPC chromatogram of Dex6G4 
 
 
Figure 2.13: GPC chromatogram of Dex100G16 
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Table 2.4: Mn, Mw and PDI of the dextrans and alkylglyceryl dextrans 
sample Mn Mw PDI 
Native dextran 
6 kDa 
4223 9811 2.3 
Native dextran 
100 kDa 
24919 109399 4.4 
Dex6G4 3640 5469 1.5 
Dex100G16 186810 188308 1.0 
Where: Mn = number average molecular weight 
               Mw = weight average molecular weight 
                PDI = Polydispersity index 
 
 
 
2.4.3 MALDI-TOF MS 
 
Figure 2.14: MALDI TOF spectrum of Dex6G4. 
Peak-to-peak mass differences of 130.2 and 146.2, observed between the main peaks 
that form the spectral pattern, are likely due to fragmentation at the O-C bond level (as 
suggested in Figure 2.14, insets); this is indicative of a fragmentation pathway that is 
characterised by the loss of C7H14O2 and C7H14O3 (MW 130.18 and 146.18 Da, 
respectively), which in turn confirms the successful chemical grafting of native dextran 
with butylglyceryl pendent chains; no cross-ring fragments could be identified.  
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The isotopic ratios (discernible in Figure 2.15) are indicative of primarily singly charged 
ions. Since the CHCA matrix used (a strong acid in the gaseous phase) tends to induce 
extensive fragmentation (Karas et al. 1995, Harvey 1999;(152, 153), the detection of 
molecular ions was not possible. This is consistent with suggestions that 2,5-
dihydroxybenzoic acid (2,5-DHB) is a better matrix for the MALDI-TOF MS study of high 
molecular weight polysaccharides (such as dextran) that require a high matrix-to-analyte 
ratio to give enhanced signals (153, 154). The mass/charge (m/z) fragment loss and 
nature of fragment loss are presented in Table 2.5. 
 
Table 2.5: Identified m/z fragment mass loss in the MALDI-TOF spectra of the modified dextrans. 
sample m/z fragment 
loss 
Nature of 
fragment loss 
identified 
Dex6G4 130.1 C7H14O2 
Dex100G4 130.1; 146 C7H14O3 
Dex100G8 ~186 C11H22O2 
Dex6G12 242.2 C15H30O2 
Dex100G12 242.3 C15H30O2 
 
 
Figure 2.15 MALDI TOF spectrum of Dex100G4 
Similar spectra have been obtained for the grafted 100kDa or 6kDa dextran (Appendix 7). 
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2.4.5 TGA 
TGA was carried out to determine the thermal stability of samples; the thermograms of 
analysed samples are collated in Appendix 6. 
 
Figure 2.16: TGA results for Dex6 
 
Figure 2.16 is the TGA plot from a sample that had been heated under nitrogen to 500°C. 
There are 2 mass loss steps: the first of these corresponds to a mass loss of -8.91% and 
exhibits a maximum mass loss rate (peak in DTG curve) at 82.5°C, while the second step 
(maximum mass loss rate at 315.0°C) is associated with a -74.25% loss relative to the 
original mass.  
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Figure 2.17: TGA results of Dex6G4 
Figure 2.17 shows the TGA profile of the sample that was heated under nitrogen 
atmosphere to 500°C. The thermogram is again associated with two mass-loss steps, the 
first of which corresponds with a mass loss of -9.01% and is characterised by a mass-loss 
rate maximum at 66.6°C; the second step (mass loss -86.6%) exhibits its maximum mass 
loss rate at 327.1°C. 
 
The thermograms of other samples are presented in Appendix 6: the data of the 
thermograms in appendices are summarised in Table 2.6; the tabulated temperature 
values were determined from the first derivative (point of inflection) of the corresponding 
thermogram.  
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Table 2.6: TGA data of first and second mass loss for modified and unmodified dextrans 
 First mass 
loss/temperature, °C 
Second mass 
loss/temperature, °C 
Total mass 
loss % 
sample % mass loss Temperature 
/°C 
mass loss Temperature 
/°C 
 
 
Dex6 -8.90 82.5 -74.25 315.0 -83.2 
Dex6G4 -9.01 66.6 -86.58 327.1 -95.6 
Dex6G8 -3.54 69.0 -77.81 388.0 -81.4 
Dex6G12 -5.36 59.7 -86.17 319.8 -91.5 
Dex6G14 -4.39 61.7 -86.49 305.9 -90.9 
Dex6G16 -2.85 58.1 -87.70 252.6 -90.6 
Dex100 -9.38 84.2 -70.63 304.6 -80.0 
Dex100G4 -9.70 66.0 -76.63 326.5 -86.3 
Dex100G8 -6.41 61.6 -77.30 328.8 -83.7 
Dex100G12 -4.95 59.1 -90.60 335.6 -95.6 
Dex100G14 -4.82 74.4 -86.00 309.2 -90.8 
Dex100G16 -3.12 24.3 -90.08 332.6 -93.2 
 
 
All thermograms exhibit two decomposition stages: the first mass loss, which occurs 
below 100°C, is attributed to water loss from the sample while the second mass loss, 
which occurs in the temperature range 200-350°C, is due to the degradation of the 
alkylglyceryl dextran structure (155, 156).  
 
To determine the trend of water content loss across the range of materials, percentage 
mass losses were plotted against chain lengths. 
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Figure 2.18: first-stage mass loss as a function of chain length (Dex100 and derivatives) 
 
 
Figure 2.19: first-stage mass loss as a function of chain length (Dex6 and derivatives) 
 
In accord with expectation, the first mass loss (loss of water) varies with chain length, 
with more hydrophilic samples exhibiting correspondingly higher percentage mass loss 
(Figures 2.18 and 2.19): the longer the chain length, the more hydrophobic the sample 
and the lower its water content. Accordingly, for samples of Dex100 kDa (Figure 2.18), the 
plot reveals the gradual decrease in water content. A similar behaviour was observed for 
samples of Dex6kDa (Figure 2.19), with Dex6G8 presenting the only anomaly.  
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2.4.6 Discussion on synthesis and characterisation techniques 
Matrix-assisted laser desorption/ionisation mass spectrometry (MALDI MS) has been 
developed as a soft ionisation and as a sensitive method that allows the rapid detection 
of macromolecules and biopolymers (157). MALDI can generate singly or multiply charged 
ions ([M+nH]n+), the prevalence of which depends on the nature of the matrix, the laser 
intensity and/or the voltage used. While it is generally accepted that the MS analysis of 
polysaccharides is of lower sensitivity than that of peptides and proteins, it has been 
shown that MALDI-TOF MS may be usefully applied to the measurement of the molecular 
mass of carbohydrates up to 106 Da (158); it has been recently acknowledged however 
that this becomes more difficult for higher molecular weights as neutral polysaccharides 
show poor ionisation efficiency (154). Figure 2.15 presents a typical MALDI TOF spectrum 
of the modified dextran polymers considered in this study. The spectra are characterised 
by the lack of a molecular ion and of patterns that are characteristic of natural glycans, 
and a series of glycosidic ions. The observed pattern is attributed to the loss of 
butylglyceryl chains, which is consistent with the successful chemical modifications of 
dextran. 
The mechanism for the attachment of alkyl glycerol chains to dextran involves the t-BuOK 
-mediated deprotonation of the alcohol moieties of dextran to the strongly nucleophilic 
butoxide ion, which in turn attacks the strained glycidyl ether ring (149).  
Since the viscosity of the reaction medium, which is influenced by both the length of the 
alkyl chains and the concentration of t-BuOK, appeared to impact upon the fate of the 
reaction, preliminary experiments were conducted in order to determine optimised 
mixing ratios for the reactants. An attempt to reduce the viscosity of the reaction medium 
by increasing the amount of solvent (DMSO) by 30% did not produce the desired effect. 
By contrast, modulation of the ratio of t-BuOK to alkyl glycidyl ether increased the extent 
of the functionalisation. For optimal functionalisation, the ratio 1:3:4 (dextran: t-BuOK: 
alkyl glycidyl ether) was used for the shorter chain butyl- and octyl- glycidyl ethers; the 
corresponding ratio of 1:2:1 was selected for the modification of dextrans with lauryl 
glycidyl ether; the ratio of 1:1:1 was used for the reaction involving the tetradecyl glycidyl 
and hexadecyl glycidyl ethers.   
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 As expected, GPC experiments showed that the higher the degree of substitution or the 
chain length of the sample the higher the corresponding molecular weight.  All other 1H- 
and 13C-NMR signals were in good agreement with those expected on the basis of 
published work (159). 
 
2.5 Conclusions  
Alkylglyceryl dextrans have been synthesised by the reaction of commercially available 
dextrans and a range of alkyl glycidyl ethers in the presence of a strong base (t-BuOK) in 
anhydrous DMSO and under an atmosphere of nitrogen. The crude products were 
washed with organic solvent, subjected to dialysis, and freeze-dried to a final yield of 40-
60% before characterisation with NMR and FTIR. NMR spectroscopic investigations 
showed that the degree of substitution was in the range 50 - 145%. 
Thermograms of the alkylglyceryl dextrans have shown a two-step mass loss profile that 
corresponds to the initial loss of water and the higher-temperature thermal 
decomposition of the dextran core. TGA measurements revealed that the water content 
of each dextran and modified dextrans is influenced by the length of the hydrophobic side 
chain. 
GPC data showed that butylglyceryl dextran (Dex6G4) has an average molecular weight 
that is lower than that of the 6kDa native dextran. By contrast, Dex100G16 exhibits an 
average molecular weight that is higher than that of the native dextran (Dex100), which is 
attributed to the contribution of the pendent alkylglycerol chain. 
Due to extensive fragmentation of the modified dextrans and to the absence from the 
spectra of molecular ion peaks, MALDI-TOF MS did not prove suitable for the 
determination of the molecular weight of samples. 
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3. Preparation and characterisation of nanoparticles 
The preparation of nanoparticles of poly(alkyl cyanoacrylate) was carried out by anion-
propagated emulsion polymerisation and solvent-displacement nanoprecipitation, 
whereas the preparation of nanoparticles of PLA-alkylglyceryl dextran was by means of 
the dialysis method. 
3.1 Mechanism of ACA polymerisation 
The method of choice for the chemical synthesis of alkyl cyanoacrylates (ACA) is the  
Knoevenagel condensation reaction (73). ACA molecules polymerise readily at room 
temperature in the presence of any nucleophile, base or even trace moisture to yield 
PACA polymers. In solution, PACA polymers are highly susceptible to rapid degradation 
into species of lower molecular weight, which is witnessed as anomalous solution-
viscosity behaviour (160). The low ceiling temperature of PACA has been linked to retro-
Knoevenagel depolymerisation (161). 
The polymerisation of ACA has been examined in depth by Ryan and McCann, who have 
made the following observations: (i) the ACA monomer and polymer are in rapid, dynamic 
equilibrium; (ii) a very high concentration of monomer relative to that of the initiator 
favours the production of long chains; (iii) chain-termination occurs by the anionic end-
group becoming protonated by water or other acid functionalities to form a species that 
is not capable of carrying the reaction; (iv) the use of base effects a deprotonation of this 
dormant chain end, allowing the reactivation of the polymerisation reaction; (v) the 
monomer that is present during the equilibrium adds rapidly to any nucleophiles present 
to initiate new-chains formation; (vi) since the concentration of the monomer in the new 
equilibrium is much lower than that during polymerisation, the new chains that form have 
drastically lower molecular weights (implying that longer-chain formation is favoured by 
the distortion of the monomer to polymer ratio through the continuous addition of 
monomer into the polymerisation vessel); and, (vii) the addition of acid into the reaction  
mixture inhibits the deprotonation of the chain ends, preventing the establishment of the 
equilibrium (160). 
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The most widely used alkyl cyanoacrylate monomer is ethyl cyanoacrylate (ECA). As with 
other alkyl cyanoacrylates, anionic species or a Lewis base are both capable of initiating 
the rapid polymerisation of this monomer to give a high molecular weight polymer; 
amines and phosphines are adequately nucleophilic substances for the purpose. The 
degree of substitution in amines affects reactivity, with tertiary amines initiating an 
exothermic polymerisation that results in the formation of high molecular weight 
polymers; primary and secondary amines give polymers of lower molecular weights (162).  
 
The high reactivity of alkyl cyanoacrylates is consequent to the electron withdrawing 
effect of the ester and nitrile functionalisation of the monomer unit. The effective 
utilisation of alkyl cyanoacrylates in nanoparticles formulation involves polymerisation, 
which requires a nucleophile or base for the reaction initiation; water, amines, alcohols 
and phosphines are employed commonly. The combination of the monomer with the 
initiating nucleophile results in the formation of a chain-carrying species that is stabilised 
by the ester and nitrile moieties, while the associate polarisation of the double bond 
activates further nucleophilic attack. Chain propagation occurs by the repetitive addition 
of electron deficient monomer to the anionic end of the growing chain and further to the 
biomedically useful polymer (Figure 3.1). The hydrogen bonds between ammonium  and 
cyano  groups that become established during the polymerisation of ACA coupled with 
van der Waals interactions represent the forces of attraction that are responsible for the 
cohesion of PACA nanoparticles that are important in their use as biomedical materials 
(163). 
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Figure 3.1:  Mechanism for the anionic emulsion polymerisation of ACA, as initiated by mild nucleophiles (164). 
 
3.2 Materials and instrumentation  
Ethyl-2-cyanoacrylate, dextrans (100 and 6 kDa), ethyl-2-cyano-3-ethoxyacrylate (Sigma-
Aldrich), butyl cyanoacrylate (donated by Henkel Ireland) and dimethyl sulfoxide (DMSO; 
anhydrous, ≥ 99.9 %) were sourced from Sigma-Aldrich, UK.  Dicyclohexylcarbodiimide 
(DCC, ≥ 99 %,) was obtained from Fluka. Poly(lactic acid) with free carboxyl group (PLA, 
MW 15 kDa) was obtained from Purac, Netherlands. Ultrapure water (18.2 mΩ) was 
obtained using a Triple Red instruments. All reagents were used as obtained. The dialysis 
purification step of PLA-alkylglyceryl-dextrans was performed in a discontinuous system 
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(deionised water, 15.0 mΩ, 10.0 L; exchanged 3 times/day) using Visking membrane 
tubing (Medicell International Ltd, UK; cut-off either at 12-14 kDa or at 3.5 kDa). 
Alkylglyceryl dextran of different chain lengths. Low speed centrifugation was performed 
by means of a Rotofix 32A Hettich (Zentrifugen-Germany). Ultracentrifugation 
experiments utilised a Beckman Ultracentrifugation XL-90 instrument. The Z-average 
diameter (nm), PDI and zeta potential (mV) were determined by Dynamic Light Scattering 
experiments (Malvern Zetasizer Nano instrument, Worchester, UK) using Whatman filter 
paper of specified pore size for filtration. Freeze drying involved the use of either a Virtis 
(Advanced Sentry 2.0 Controller for Virtis® Benchtop(TM) or a 'K' Freeze Dryer (SP 
Industries-Warminster, USA) instrument. Sonication was by means of a Grant ultrasonic 
bath XB3 (Farnell, UK).  
 
TGA analysis was carried out with TG 209 F1 Libra (TGA from Netzsch Instruments), with 
temperature ranged from 25 to 500°C, heating at 10K/min. under Nitrogen atmosphere. 
Nanoparticle Tracking Analysis (NTA) was carried out at 25 °C using a Nanosight 
instrument that was equipped with a thermostatted LM-14 unit and with a 532 nm 
(green) laser. The image capture (length 60 s) was by means of a CCD Marlin camera, data 
were analysed using NTA 3.0 software. 
 
The hydrodynamic diameter of the nanoparticles was determined with DLS using a 
Malvern Zetasizer Nano instrument, UK, equipped with a 633 nm He-Ne laser (173° back 
scattering angle detection; Zetasizer software v.7.01 software). Samples analysis was 
done in triplicate (25 °C, 2 min equilibration) using clear polycarbonate disposable 
cuvettes. Data are presented as Z averages (Z-av.) and the associated polydispersity index 
(PDI). 
 
The autotitrations of colloidal material were performed to simultaneously determine Z-
average diameter (Z-av) in (nm), and ZP (mV) as a function of pH; an MTP-2 (Multi-
Purpose Titrator-2, Malvern, UK) equipped with a solvent degasser was employed. The 
sample (10 mL) was titrated automatically against aqueous NaOH solutions (5 mM or 50 
mM) and against aqueous HCl solutions (5 mM or 50 mM). Prior to each experiment, 
solutions were filtered through 0.2 μm PES filters (Whatman). 
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3.3 Methods 
3.3.1 Attempted NP formulation with ethyl 2-cyano-3-ethoxyacrylate  
Since there are few reports regarding the capability of ethyl 2-cyano-3-ethoxyacrylate 
(Figure 3.2) to undergo co-polymerisation to nanoparticulate structures, an attempt was 
made to formulate nanoparticles by means of an anionic emulsion polymerisation 
protocol (24, 93). To this end, ethyl 2-cyano-3-ethoxyacrylate (1 g) was dispersed in 
acetone/water (1:1 v/v; 1 mL) and added dropwise to a solution of dextran (100 kDa; 1% 
w/v, 100 mL) in KH2PO4 buffer (pH 2.5). The mixture was allowed to stir overnight (room 
temperature), after which time it was neutralized with NaOH solution (1 N), filtered 
through 0.8 µm filter paper and centrifuged (90000 g, 1 h).  
 
Figure 3.2: Structure of ethyl 2-cyano-3-ethoxyacrylate 
 
Since no solid product could be isolated, attempts were made to repeat the experiment 
at increased pH, in water-free acetone and in the absence of phosphate buffer. All these 
attempts failed to produce polymeric structures, suggesting that this molecule is not 
amenable to polymerisation under the selected experimental conditions. Hence, ethyl 2-
cyano-3-ethoxyacrylate was excluded as a co-monomer in further nanoparticle-formation 
experiments, limiting the choice of cyanoacrylates to the ethyl and butyl homologues. 
3.3.1.1 Preparation of PECA-Dex100 nanoparticles  
Method: PECA-Dex100 was prepared using a standard literature method (24,93). Ethyl 2-
cyanoacrylate (1 mL) was added dropwise into dextran solution (1% (w/v), 100 mL, pH 
2.5; 100 KDa) and the solution was allowed to stir at room temperature overnight. After 
this time, the mixture was neutralised with NaOH solution (1 N), centrifuged (Rotofix; 
3500 rpm, 20 min), filtered  (0.8 µm Whatman filter paper), isolated by 
ultracentrifugation (18000 g, 30 min; Beckman ultracentrifuge), rinsed with deionised 
water and re-suspended in deionised water (5 mL; sonication in water bath, 10 min). The 
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size and zeta potential of the thus suspended nanoparticles was determined using a 
Malvern instrument before the water was removed (freeze dryer, 24 h). The synthesis of 
PECA repeated in phosphate buffer medium resulted in the formation of NPs that were 
characterised by poor yield, low zeta potential and high conductivity. 
 
3.3.2 Preparation of poly (ethyl 2-cyanoacrylate)–alkylglyceryl-dextran NPs 
Method 1 (24, 93): Ethyl 2-cyanoacrylate (ECA) (600 µL) was added dropwise to 
alkylglyceryl-dextran (DexnGm; 100 mg; n=6 or 100; m=4, 8, 12, 16) dispersed in water 
(100mL; pH 2.5, HCl) and stirred at room temperature for 4 h (Figure 3.3). After this time 
the solution was neutralised with NaOH solution (1 N), centrifuged for 15 min (3000 rpm; 
Rotofix) and further ultra-centrifuged for 30 min at 12,200 rpm (18000 g; Beckman 
ultracentrifuge). The isolated sample (pellet) was rinsed, dispersed in water and sonicated 
for 10 min before freeze drying to a batch-dependent yield in the range 20-40%.  
 
Figure 3.3: Schematic representation of the protocol for the synthesis and characterisation of PACA-alkylglyceryl 
dextran. 
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Method 2 (69): ECA (600 µL) was dissolved in acetone (100 mL) and gradually added 
(room temperature) to a stirring solution of alkylglyceryl dextran (DexnGm; 100 mg) in 
water (100 mL); stirring was continued overnight at room temperature to allow the 
evaporation of most of the acetone. Following centrifugation at 40000 rpm for 30 min, 
the pellet was rinsed, re-suspended in water and subjected to sonication for 10 min 
before isolation by freeze drying to a batch-dependent yield in the range 50-70%. 
Method 3 (24): ECA (1 mL) was added dropwise to DexnGm (1% w/v; pH 2.5, HCl) and was 
allowed to stir for a minimum of 4 h at room temperature, before neutralisation with 
NaOH solution (1 N), filtering (P3 glass filter), and isolation by centrifugation (12200 rpm, 
30 min). The crude product was rinsed, dispersed in water (10 mL), sonicated (10 min) 
and freeze dried to a yield of 30-40%. SEM image of PECA-Dex100G4 is in Appendix 4. 
3.3.3 Preparation of PLA15-Dex100G8-PECA  
Alkylglyceryl dextran, PLA and ECA were all incorporated into a single multi-block 
structure through the simple polymerisation procedure of nanoprecipitation solvent 
displacement.  
Dex100G8 (0.05 g) was dispersed (by sonication) into an acetone (50 mL) solution of ECA 
(0.265 g) and PLA (0.265 g). This mixture was then added dropwise in water (100 mL; 18.2 
mΩ) under continuous stirring. After overnight stirring at room temperature, the mixture 
was dialysed in a discontinuous manner (10 L container; 3x a day for 2 days), filtered 
(Whatman paper, 90 mm; 1 qualitative circle) placed over sintered glass (P3) and the 
filtrate was freeze dried before being subjected to characterisation by DLS (Table 3.8), 
TGA (Figure 3.18), DSC (Figure 3.19) and 1H-NMR (Figure 3.17).  
3.3.4 Effect of filtration on size of PECA-Dex100G8 NPs 
ECA (100 mg) in acetone (100 mL) was gradually added to stirring Dex100G8 (100 mg) 
that had been dispersed in water (100 mL) and was allowed to stir at room temperature 
overnight. After this time, NaOH solution (2 mL, 0.1 N) was added to the resulting mixture 
and allowed to stir for a further 30 min before filtration over sintered glass (P3), 
centrifugation (40000 rpm, 30 min), rinsed and re-dispersion in water (10 mL).  
Following filtration (yield, 15-25%) the isolated product was characterised using DLS 
(Table 3.3) and NMR (Figure 3.5). 
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3.3.5 Preparation of PECA-Dex6G16 nanoparticles by nanoprecipitation  
ECA (600 µL) in acetone (100 mL) was added gradually to stirring Dex6G16 (100 mg) in 
water (100 mL; 18.2 mΩ). Stirring was continued overnight (room temperature) after 
which time the product was isolated by centrifugation (12200 rpm, 30 min), rinsed with 
deionised water, dispersed in water (10 mL) and sonicated (ultrasonic bath). 
3.3.6 Preparation of PLA-derived nanoparticles by zero length crosslinking 
Three different alkylglyceryl dextrans were employed for the preparation of PLA-
alkylglyceryl dextran derived nanoparticles (Figure 3.4; Scheme 1) by zero length grafting 
of PLA to alkylglyceryl dextran with N,N’-dicyclohexylcarbodiimide (DCC) (165, 166) and 
DMAP. PLA15 respectively grafted onto Dex100G4, Dex100G8 and Dex6G16 produced 
PLA15-Dex100G4, PLA15-Dex100G8 and PLA15-Dex6G16.  
 
The apparatus was dried (vacuum) and flushed with Nitrogen before use. DCC (0.045 g, 
0.2 mmol) dissolved in anhydrous DMSO (10 mL) was added with stirring to a solution of 
PLA (1.75 g, 0.11 mmol) in anhydrous DMSO (100 mL) contained within a round-bottomed 
flask that had been equipped with a Nitrogen inlet tube. After 30 min, the solution was 
transferred into a stirring solution (Nitrogen atmosphere) of octylglyceryl-dextran 
(Dex100G8, 0.85 g) and 4-(dimethylamino)-pyridine (DMAP; 0.026 g, 0.22 mmol) in 
anhydrous DMSO (100 mL) that had been stirred for an hour. The reaction mixture was 
allowed to stand at room temperature for 24 h, after which time it was filtered through 
Whatman paper over P3 sintered glass (to remove dicyclourea (a byproduct of the 
reaction) and dialyzed for 48 h (MWCO 12-14 kDa) against deionised water, before freeze 
drying. The dried powder was dispersed in acetone (50 mL), filtered through Whatman 
filter paper (to remove unreacted PLA) and the isolated pellet was dried under vacuum at 
room temperature. The thus dried pellet was washed with water, dispersed in deionised 
water (100 mL) and freeze dried to yield (20-30%) of the product. This was used to purify 
PLA15Dex100G8.  
 
Purification (method 2): The preparation of PLA15-Dex100G16 and PLA15Dex100G4 
nanoparticles followed the protocol presented in Figure 3.4. The zero-length grafting (165, 
166) of PLA to alkylglyceryl dextran was carried out with N,N’-dicyclohexylcarbodiimide 
(DCC). After dialysis and freeze drying, the powder was dispersed in acetone (100 mL), 
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spun at 22,000 rpm for 30 min (to remove unreacted PLA) and the pellet was dried 
overnight under vacuum. The dried pellet was suspended in deionised water (300 mL) and 
placed on a shaking platform overnight (room temperature) before freeze drying to yield a 
pellet of the material labelled PLA15-Dex100G16. To the supernatant (acetone solution 
containing mostly unreacted fraction of PLA) was added water (500 mL) to precipitate any 
unreacted PLA, which was removed by filtration. The water-acetone mixture was allowed 
to stir gently at room temperature for 48 h (to remove excess acetone), and the solid mass 
that formed (yield 50-70%) was labelled PLA15-Dex100G16-acetone fraction.  
 
 
Figure 3.4 scheme for the synthesis of PLA-alkylglyceryl dextran nanoparticles 
 
3.3.7 Preparation of PBCA-Dex100G4 nanoparticles  
BCA (200 mg) was added gradually into a stirred suspension of Dex100G4 (200 mg) in 
water (100 mL) and the mixture was allowed to stir for a further 4 h at room temperature. 
After this time, the mixture was neutralised with NaOH solution (1 N), filtered through 
sintered glass, centrifuged (40000 rpm, 30 min) and the nanoparticles that separated 
were rinsed with water, sonicated, dispersed in water (20 mL) and freeze dried to a yield 
of 26%. This product was characterised with DLS and NTA. 
3.3.8 Degradation study 
The esterase-induced study of the degradation of PECA-Dex100G4 was conducted 
according to a standard literature method (167, 168): ECA (2.5 g, 2.36 mL) was added 
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dropwise to water (250 mL; 18.2 mΩ, pH 3) that contained Dex100G4 (250 mg;   0.1% 
w/v) and maintained at 25°C (water bath) and stirred for 3 h. After this time, specified 
concentrations (1-5 mg/mL) of an esterase solution in phosphate buffer (pH7) were 
added to each NPs suspension (3.5 mL) contained in 30 mL of Ringer’s solution. The 
resulting mixtures were incubated at 37°C under shaking (50 cycles/min). Aliquots were 
withdrawn after 0.5 h, 1 h, 2 h, 3 h and 4 h and size and PDI were determined using DLS. 
The same procedure was repeated with samples at a constant esterase concentration of 2 
mg/mL and also with an esterase-free mixture (which served as control). 
The effect of increased enzyme concentration on the degradation pattern of PECA-
Dex100G4 
The methods adopted for the formulation of nanoparticles and for the study of their 
degradation were identical to those described previously (167, 168); with the only 
variations for the latter study being the duration of the experiment, which was prolonged 
and the  concentration of enzyme that was increased (Table 3.1). A mass of 31 mg of 
PECA-Dex100G4 contained in a 3.5 mL volume of each suspended population of 
nanoparticles was used as substrate for the degradation study. A stock solution of the 
enzyme (180 mg in 15 mL; equivalent to 12 mg/mL) was made and distributed amongst 
the samples under test as indicated in Table 3.1. Samples were incubated at 37°C (Grant 
OLS 200 orbital/linear shaking water bath) under shaking (50 rpm/min); the extraction of 
aliquots at premeditated time points allowed the measurement of size and the 
determination of PDI by DLS. 
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Table 3.1: protocol for the degradation study of PECA-Dex100G4 NPs 
sample A B C D E F 
Enzyme (mg) - 7.06 12.94 24.71 36.47 71.75 
Units of Enzyme - 120 220 420 620 1220 
Enzyme Vol. (mL; 
conc. 12mg/mL) 
- 0.588 1.078 2.059 3.04 5.98 
Ringer’s Solution 
(mL) 
30 30 30 30 30 30 
Nanoparticles 
(mL) 
3.5 3.5 3.5 3.5 3.5 3.5 
 
 
3.4 Results and discussion 
3.4.1 Preparation of nanoparticles of ethyl 2-cyanoacrylate 
3.4.1.1 Preparation of PECA-Dex100 NPs 
The yield of PECA-Dex100 NPs (2.41%), was very poor as compared with that reported by 
Han et al. (108) who, using a similar method, reported a yield of over 93%. Three batches 
of NPs were prepared, all of which produced nanoparticles of reproducible size in the Z-
average diameter range 250-400 nm and PDI of 0.364. 
3.4.1.2 Preparation of poly (ethyl 2-cyanoacrylate)–alkylglyceryl-dextran NPs 
3.4.1.2.1 Preparation of PECA-Dex6G16 NPs by nanoprecipitation  
This method combines the emulsion polymerisation, solvent evaporation and 
nanoprecipitation methods into a one-pot synthesis. As the acetone evaporates the 
acetone-soluble ECA is allowed to react via an  anionic mechanism leading to 
instantaneous nanoprecipitation. The presence of acetone appears to play an important 
role in regulating the size and size distribution of the formed nanoparticles (Table 3.2), 
which is very small (153.3 nm) as compared with that of nanoparticles obtained from 
conventional anionic polymerisation. 
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Table 3.2: DLS Characterisation PECA-Dex6G16 nanoparticles (n=1) 
Parameter  value 
Zeta Av. diameter 153.3±0.4 nm 
PDI 0.132±0.006 
Zeta potential -27.6±0.7 mV 
 
 
3.4.1.2.2 Effect of filtration on size of PECA-Dex100G8 NPs 
A study was conducted in an effort to evaluate the effect of filtration on the size, PDI and 
zeta potential of the nanoprecipitation-solvent-displacement-method formulated PECA-
Dex100G8; nanoparticles were characterised by DLS (Table 3.3) and NMR (Figure 3.5). 
 
To evaluate the effect of filtration, poly(ethersulfone) (PES) filter membrane (0.45 µm) 
was used for the filtering of a portion of the dispersed sample before DLS analysis (Table 
3.3) – no significant differences were observed between the filtered and unfiltered 
samples.  
 
Table 3.3: Effect of filtration on NPs size, PDI and zeta potential (±SD; n=3) 
 
 
parameter Un-filtered Filtered  
Size (Z-av.d)nm 120.94±30.57 110.77±29.12 
PDI 0.22±0.02 0.18±0.00 
Zeta (mV) -38.37±1.12 -31.39±0.90 
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Figure 3.5: 
1
H NMR spectrum of PECADex100G8 nanoparticles 
NMR spectrum PECA-Dex100G8 (Figure 3.5) shows that at least two of the characteristic 
resonances of PECA are well defined, namely those at 1.3 ppm and at 4.2 ppm. The 
spectral features of alkylglyceryl dextran are less pronounced (Figure 3.5), as is consistent 
with the high ratio of PECA to alkylglyceryl dextran. This confirms data from elemental 
analysis determinations, which estimated the ratio of PECA to alkylglyceryl dextran at ca. 
90:10. The 1H- and 13C-NMR spectra of pure PECA are respectively presented in Figures 
3.6 and 3.7.  
f 
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Figure 3.6: 
1
H-NMR spectrum of pure PECA 
 
Figure 3.7: 
13
C-NMR spectrum of pure PECA 
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3.4.2 Elemental analysis results 
The method for the formation of nanoparticles appeared to be of little influence on the 
elemental composition and hence to the ratio of PECA to alkylglyceryl dextran in the 
nanoparticulate formulation. The nanoparticles evaluated for elemental composition and 
ratio of PECA to alkylglyceryl dextran had been formulated by: (i) anionic emulsion 
polymerisation (samples 1-8); or (ii) the nanoprecipitation-solvent-diffusion method 
(samples 9-10; Table 3.4). 
 
Elemental analysis enabled the determination of the ratio of PECA to alkylglyceryl-dextran 
in complex nanoparticles (Table 3.4). The percentage ratio of alkylglyceryl dextran and 
PECA of the polymer obtained in the experiment was deduced by considering their 
percentage composition of carbon, nitrogen, oxygen, and hydrogen following the 
equation presented in Appendix 11. Experimental elemental compositions were in 
agreement with theoretically calculated values.  Across the range of synthesised 
nanoparticles, PECA was the higher percentage constitutional unit (over 90% in some 
samples) while alkylglyceryl-dextran accounted for a small percentage (3.9% to 19.62%) 
of the structural component of nanoparticles (Table 3.4).   
 
Elemental analysis reported for the respective composition percentage weight per weight 
(w/w) of dextran and poly (isobutyl cyanoacrylate), PIBCA, in a polymer obtained from the 
emulsion polymerisation of isobutyl cyanoacrylate (IBCA) is 22% and 78% (169), which is 
consistent with current findings in that the ratio of dextran to alkyl cyanoacrylate is 
consistently low. This observation is in agreement with that from comparative 
(alkylglyceryl-dextran to PECA) NMR experiments which were characterised by the low 
intensity of signals from alkylglyceryl-dextran moieties as compared with those from alkyl 
cyanoacrylate groups (Figure 3.5). Since it has been observed that sequential washing and 
centrifugation of nanoparticles from dextran and BCA reduces the PBCA:dextran ratio to 
9:1, it may be reasonably assumed that a significant amount of dextran is simply 
physisorbed onto the nanoparticles (170). 
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Table 3.4: Percentage elemental composition of PECA-alkylglyceryl dextran NPs (experimentally found and calculated) 
S/No Material  g %DS X %PECA (w) %Dex-G 
(w) 
Found 
(av%C) 
Cal C.% Found 
(av%H) 
 Cal. 
(H%) 
Found 
(av%N) 
 Cal.(%N) av%O(100-
CHN) 
1 PECA 
Dex6G4 
4 87.7 26.29 92.25 7.75 55.94 57.22 5.77 5.83 10.33 10.33 27.96 
2 PECA 
Dex100G4 
4 68.49 26.66 92.99 7.01 56.07 57.17 5.81 5.79 10.41 10.41 27.71 
3 PECA 
Dex6G8 
8 114.94 10.21 80.38 19.62 56.31 58.03 6.34 6.51 8.65 8.65 28.70 
4 PECA 
Dex100G8 
8 64.91 46.35 95.92 4.079 56.22 57.51 5.73 5.78 10.67 10.67 27.38 
5 PECA 
Dex6G12 
12 54.35 31.04 94.34 5.66 56.31 57.61 5.89 5.88 10.41 10.41 27.39 
6 PECA 
Dex100G12 
12 67.56 49.07 96.09 3.91 56.35 57.69 5.82 5.83 10.63 10.63 27.19 
7 PECA 
Dex6G16 
16 133.33 19.84 88.09 11.91 56.95 59.36 6.45 6.61 9.13 9.133 27.47 
8 PECA 
Dex100G16 
16 144.92 17.32 86.07 13.93 57.22 59.78 6.58 6.80 8.78 8.78 27.42 
9 PECA 
Dex10G4A 
4 68.49 36.92 94.84 5.159 56.81 57.29 5.67 5.75 10.62 10.62 26.90 
10 PECA 
Dex100G16A 
16 144.92 18.85 87.05 12.95 57.99 59.63 6.35 6.72 8.94 8.94 26.73 
g = no of C atoms in the alkyl group present in the pendent chain (in substituted dextran) 
%DS = the degree of substitution of dextran with pendent chains (as calculated by NMR) 
X = molar ratio (ECA monomer : dextran glucopyranose units) 
ECA C6H7NO2    
Dex C6H10O5    
G C(g+3)H(2g+6)O2   
(equations in Appendix 11) 
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For the 1H-NMR determination of the percentage degree of substitution (%DS) of 
modified dextran used for nanoparticles formulation, the ratio of the intensity of the 
resonance integral of the terminal methyl of the alkylglycerol chain (A) was divided by 
three-times (corresponding to the ratio of attaching protons) the intensity of the integral 
of the signal due to the anomeric proton of the pyranose ring of the glucose unit of 
dextran (equation 3.1). As expressed, %DS is defined as the number alkylglycerol chains 
attaching per 100 glucose units of dextran (171) normalised with reference to the 
maximum theoretical percentage of 300 for the fully –OH substituted pyranose groups 
structure. 
100*
3
%
B
A
DS     (eq. 3.1) 
 
3.4.3 MALDI-TOF-MS of PECA-alkylglyceryl dextran NPs 
 
Figure 3.8 MALDI TOF spectrum of PECADex6G4 
PECA-Dex6G4 NPs Peak to peak mass differences between neighbouring peaks was ca. 
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fragment. The spectrum exhibits the characteristic features of carbon-oxygen bond 
fragmentation (Figure 3.8). 
 
Figure 3.9: MALDI TOF spectrum of PECA-Dex6G12 
 
 
 
PECA-Dex6G12 NPs characteristic peak-to-peak mass differences was ca. 125 Da, 
indicating that PECA was eliminated by means of carbon-oxygen bond fragmentation 
(figure 3.9). Other spectra were appended in (Appendix 8).  
The most characteristic fragment mass loss was that of PECA, which is consistent with the 
80-90% proportion of PECA that was calculated from elemental analysis data. This large 
percentage of PECA structural units in nanoparticle structures may account for the mass 
loss of 125 Da observed for most nanoparticles except those from PECA-Dex100G4 and 
PECA-Dex6G4 that had peak differences of 130 Da (Table 3.5) and those from 
PECADex6G8 (Table 3.5) which did not have consistent characteristic of 125 Da peak-to-
peak fragment mass difference (172).  
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Table 3.5: m/z fragment mass loss of PECA-alkylglyceryl dextran NPs 
sample m/z fragment 
mass 
Nature of 
fragment loss 
PECA-Dex6G4 130.1,114.2 C7H14O2 
PECA-Dex100G4 130.2 C7H14O2 
PECA-Dex6G8 125.1 C6H7NO2 
PECA-Dex100G8 125.1 C6H7NO2 
PECA-Dex6G12 125.1,16 C6H7NO2 
PECA-
Dex100G12 
125.1 C6H7NO2 
PECA-Dex6G16 125.1 C6H7NO2 
PECA-
Dex100G16 
125.1 C6H7NO2 
 
3.4.4  Autotitration of PECA-alkylglyceryl dextran nanoparticles  
To evaluate the stability of the nanoparticles, there was carried out an automatic pH 
titration of PECA and PECA-alkylglyceryl nanoparticles (Figures 3.10-3.14) against aqueous 
HCl (0.005/0.05M). Data show that the zeta potential of PECA nanoparticles and PECA-
alkylglyceryl dextran nanoparticles decreases with decreasing pH. 
PECA-alkylglyceryl dextran nanoparticles (PECA-Dex6G4 (1:1), PECA-Dex6G4 (1:6), PECA-
Dex6G16 (1:1), PECA-Dex6G16 (1:6); respectively presented in Figures 3.11; 3.12, 3.13 
and 3.14) and PECA nanoparticles (Figure 3.10) were all assessed for their stability at 
different pH environments. The Z-averaged diameter (nm) and zeta potential (mV) were 
determined (MPT-2 Malvern instruments) as a function of pH over the range of ca. pH 3-8 
using HCl solutions as titrants (0.005 M and 0.05 M). Protonation/deprotonation 
processes may explain the slight variations in the size of nanoparticles under different pH 
conditions.  
 The observed pH-induced decreases in the size of PECA-NPs (Figure 3.10) and PECA-
Dex6G4 (1:1) NPs (Figure 3.11) are not statistically significant (p<0.05, ANOVA; Table 3.6). 
Similarly, the average sizes of PECA-Dex6G4 (1:6) NPs (Figure 3.12), PECA-Dex6G16 (1:1) 
NPs (Figure 3.13) and PECA-Dex6G16 (1:6) NPs (Figure 3.14) were all little influenced by 
pH. The pH-induced differences in the measured zeta potentials of PECA NPs (Figure 3.10) 
and PECA-Dex6G4 (1:1) were not statistically significant (p<0.05) but those of other NPs 
exhibited considerable variation (Table 3.6). 
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Figure 3.10: Effect of pH on PECA-nanoparticles (0.25mg/mL) MPT-2 Titration-[0.005M/0.5M HCl] (n=2, ±SD) 
 
 
Figure 3.11: Effect of pH on PECA-Dex6G4 (1:1) nanoparticles (0.25mg/mL); MPT-2 Titration (0.005/0.5M HCl; n=3 
±SD) 
-50
-40
-30
-20
-10
0
10
0
100
200
300
400
500
600
700
800
7.44 6.99 6.65 5.83 5.46 5.09 4.67 4.16 3.71 3.2
Zeta potential (mV) Z.av.diameter (nm) 
pH 
size zeta
-40
-35
-30
-25
-20
-15
-10
-5
0
0
100
200
300
400
500
600
7.78 7.42 7.02 6.6 6.19 5.5 5.15 4.61
Zeta potential (mV) Z.av.diameter(nm) 
pH 
size zeta
Preparation and characterisation of nanoparticles 
78 
 
 
 
Figure 3.12: Effect of pH on the characteristics of PECA-Dex6G4(1:6) nanoparticles (0.25mg/mL);  MPT-2 Titration 
(0.005/0.5M HCl; n=3 ±SD). 
 
 
Figure 3.13: Effect of pH on PECA-Dex6G16(1:1) nanoparticles (0.25mg/mL);  MPT-2 Titration (0.005/0.5M HCl; n=3 
±SD). 
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Figure3.14: Effect of pH on PECA-Dex6G16 (1:6) nanoparticles (0.25mg/mL); MPT-2 Titration (0.005/0.5M HCl; n=3 
±SD). 
 
 
Table 3.6: Comparison of effects of pH on the size and zeta potential of titrated nanoparticles 
 
Sample 
Size 
Zeta 
potential 
ANOVA (p) 
1 PECA 0.262 0.193 
2. PECA-Dex6G4(1:6) 0.785 0.022 
3. PECA-Dex6G4(1:1) 0.056 0.184 
4. PECA-
Dex6G16(1:1) 
0.685 0.001 
5. PECA-
Dex6G16(1:6) 
0.158 0.000 
   (p < 0.05  significant)      
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3.4.5 Preparation of PBCA-Dex100G4 nanoparticles  
PBCA-Dex100G4 nanoparticles were characterised for size, PDI and zeta potential with 
DLS and NTA (Table 3.7), NTA (Figure 3.15) and further with FTIR (Figure 3.16). The 
functional group of interest were noted as:  C=O stretch at 1743.88 cm−1; C–O stretches in 
the range 1300 - 1000 cm−1; hydrocarbon functionalities CH, CH2 and CH3, respectively at 
2954, 1450 and 1374 cm−1; OH absorption at 3500–3200 cm−1 (168); and  CN band at 2242 
cm−1 (173).  
 
Table 3.7: Size, PDI and zeta potential of PBCA-Dex100G4 NPs (n=1) 
 DLS NTA 
Z-av.diameter(nm) 149.8±1.2 120.3±35.5 
PDI 0.394± 0.018  
Zeta potential 
(mV) 
-47.8± 2.0  
 
 
Figure 3.15: Size concentration intensity distribution of PBCA-dex100G4 NPs 
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Figure3.16 FTIR spectrum of PBCA-Dex100G4 NPs 
 
 
3.4.6 Preparation of PLA15-Dex100G8-PECA  
Alkylglyceryl dextran, PLA and ECA were all incorporated into a single multi-block 
structure through the simple polymerisation procedure of nanoprecipitation solvent 
displacement.  
PLA-Dex100G8-PECA was prepared (n=3) in nanoparticulate form with narrow size 
distribution (Table 3.8). 
 Table 3.8: Size and PDI of PLA15-Dex100G8-PECA NPs (±SD, n=3) 
           
 
 
The combination of alkylglyceryl dextran, PLA and ECA was used in an attempt to 
formulate PLA15-Dex100G8-PECA nanoparticles that are both stable in suspension and 
flexible. ECA was employed as the crosslinker that connects covalently the polymer 
chains. Since available OH groups in both PLA and alkylglyceryl dextran could serve as the 
Parameter  Value  
Z-av.diameter(nm) 143.13±1.70 
PDI 0.19±0.10 
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initiating site for the polymerisation of ECA, the covalent bond formed by PECA served as 
a link between the alkylglyceryl dextran chain on one side and the PLA on the other. 
Other intermolecular forces (H-bond and van der Waals interactions) are however 
assumed to be of significance in maintaining the nanoparticulate structure in suspension.  
The NMR spectrum of PLA15Dex100G8PECA (Figure 3.17) shows the characteristic methyl 
and methylene resonances of PLA at 1.45 ppm and 5.19 ppm, respectively; the 1.2 ppm 
signal in the spectrum of PECA is attributed to methyl protons while that at 4.2 ppm is 
assigned to the methylene proton of PECA. The anomeric proton of the pyranose ring of 
dextran is manifested at 4.67 ppm. Protons corresponding to the alkylglyceryl chain 
methyl group are observed at 0.87 ppm. 
 
Figure 3.17: 
1
H-NMR spectrum of PLA15-Dex100G8-PECA (400 MHz). 
 
3.4.7  TGA and DSC thermograms of PLA-Dex100G8-PECA 
Figure 3.18 shows the TGA plots of a sample of PLA-Dex100G8-PECA which had been 
heated to 600°C under a nitrogen atmosphere and then subjected to an oxidative 
treatment (synthetic air) to 1000 °C. 
 
 
d
c
 
a
b
z
 
f
e
R= H or
c d 
b e 
a 
f 
Preparation and characterisation of nanoparticles 
83 
 
In the temperature range up to 600 °C there are at least three mass loss steps. The major 
mass loss (51.4%) occurs at a rate (peak in DTG curve) at 168.6 °C. This step is marked by 
a shoulder (at 192.4°C) in the DTG signal, which indicates the complexity of the 
mechanism of degradation. The second step is associated with a mass loss of 42.4% and is 
characterised by a rate maximum at 333.3 °C. The final (third) step exhibits a mass loss of 
5.5 %. Exposure of the sample to synthetic air causes a further mass loss of 1.2%. 
 
Figure 3.18: TGA plots of PLA-Dex100G8-PECA NPs 
 
DSC results for the sample of PLA-Dex100G8-PECA.  
In (Figure 3.19) the sample was heated from -100 °C up to 100 °C at a heating rate of 10 
K/min. Indicative of a glass transition, the first heating cycle (blue curve) identifies a 
thermal event at 54.2 °C (midpoint) which is accompanied by a change in specific heat 
capacity of 0.444 J/g*K. The shift in heat capacity is partially overlapped by a relaxation 
event that is centred at 60.1 °C. The same plot shows a small endothermic effect, which is 
most likely associated with the onset of evaporation or that of oxidative degradation of 
some sample components. 
 
The second heating cycle (green curve) confirms the glass transition temperature of the 
sample at 49.6 °C, with a change in the specific heat capacity of 0.232 J/(g*K). The 
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endothermic relaxation effect observed during the first heating was reproduced during 
the second heating run. 
 
 
Figure 3.19: DSC of PLA-Dex100G8-PECA NPs 
 
3.4.8 Preparation of PLA-derived nanoparticles by zero length crosslinking 
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              Figure 3.20: 
1
H-NMR spectrum of PLA15-Dex100G8 nanoparticles. 
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Figure 3.21: H/H-COSY NMR of PLA15-Dex100G8 nanoparticles. 
 
 
               Figure 3.22: 
13
C-NMR of PLA15-Dex100G8 nanoparticles 
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The grafting of PLA to alkylglyceryl dextran (PLA-Dex100G8) has been successful in that it 
yielded nanoparticles that are readily dispersible in water. The nanoparticles were 
characterised with NMR spectroscopy, 1H (Figure 3.20), H/H-COSY (Figure 3.21) and 13C-
NMR (Figure 3.22). The mixing of alkylglyceryl dextran and PLA in the 1:2 ratio results in 
insufficient crosslinking as witnessed by the significant amounts of unreacted PLA that are 
removed during purification. Consequently the mixing of these materials in the 1:1 ratio, 
which will result in considerably lower loses of PLA during purification, was suggested for 
subsequent reactions.   
 
PLA15-Dex100G16(or4) nanoparticles were synthesised successfully, but their purification 
required several steps (166) and was conducted in a way that two fractions of the material 
were obtained. While both fractions of nanoparticles exhibited the characteristic 13C- and 
1H-NMR resonances of glyceryl-dextran and PLA, it was the 1H NMR spectra of the 
acetone fraction that showed PLA and alkylglycerol chain resonances that were of notably 
higher intensity than that of dextran, as is desirable. The acetone fraction was associated 
with the dominant yield of 50-70%.  
 
The chemical shifts of 13C-NMR and 1H-NMR of dextran were in agreement with published 
data (159, 172, 174-177), with characteristic features in their ranges 65 ppm to 99 ppm for 
13C NMR, and 3 ppm to 5.2 ppm for 1H NMR. Slight variations in the observed chemical 
shifts  are attributed to solvent effects (178). The chemical shifts of PLA both in 13C- and 
1H-NMR were consistent with the structure of PLA, exhibiting 13C-NMR multiplets at 
169.53-169.75 ppm (–CO), 69.23 ppm (–CH), and 17.00 ppm (–CH3), and 
1H-NMR 
resonances at 5.19 ppm (CH) and 1.46 ppm (CH3); the observed chemical shifts correlate 
well with published data (179, 180). 
 
3.5 Enzymatic degradation of PECA-alkylglyceryl dextran nanoparticles 
The degradation study of PECA-Dex100G4 nanopaticles, along with that of a control 
sample, was conducted at constant enzyme concentration and variable enzyme 
concentration. The use of heat to stop the degradation process resulted in the formation 
of cloudy solutions, which could not be utilised effectively for further analysis.  
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The measurement of size and PDI by DLS did not reveal any statistically significant 
differences in the degradation behaviour of control and enzyme-containing PECA-
Dex100G4 nanoparticles (Figure 3.23, 3.24 and 3.25). It is possible that the amount or 
activity of the enzyme utilised was not sufficient to bring about the significant 
degradation of the nanoparticles within the timescale of the experimental protocol, 
especially since the degradation of PECA-Dex100G4 NPs was found to be dependent on 
both time and enzyme concentration: the longer the time of the experiment or the higher 
the concentration of the enzyme, the faster the degradation. Notably, PECA-nanoparticles 
are known to be susceptible to surface degradation (181). 
 
 
Figure 3.23: Effect of time on size and PDI of PECA-Dex100G4 nanoparticles (n=3, ±SD; control, no enzyme) 
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Figure 3.24: Effect of constant enzyme concentration on size and PDI of PECA-Dex100G4 nanoparticles (n=3, ±SD). 
 
 
Figure 3.25: Effect of enzyme concentrations on size and PDI of PECA-Dex100G4 nanoparticles (n=3, ±SD). 
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The effect of increased enzyme concentration on the degradation pattern of PECA-
Dex100G4 NPs 
 
 
Figure 3.26: Enzyme-mediated degradation of PECA-Dex100G4 nanoparticles during the first 4h of the extended 
study (0, 1 and 4 h time points) for different enzymatic activity (A= 0 units; B= 120 Units; C= 220 Units; D= 420 units; 
E=620 units; F=1220 units). 
 
Consideration of the data for the first 4 h of the 84 h degradation study, for all the sample 
sets there was an apparent decrease in size during the first hour of the experiment 
(Figure 3.26), and also between aliquots of A, B and C sampled at the first- and fourth-
hour periods;  this is in agreement with published data on PBCA nanoparticles (168). 
Aliquots of D, E and F sampled at four hours from the onset of the experiment exhibited 
increased sizes relative to those sampled at one hour. The increases in the size of D, E, 
and F after four hours of incubation with the enzyme were witnessed as initiation of 
aggregation. The increase appears to be directly related to enzyme concentration. In 
accord with the findings of Muller et al. (181), who reported the NaOH-induced surface 
degradation of PECA-nanoparticles, the degradation pattern observed with samples A, B 
and C could be consequent to surface degradation whereby PECA becomes depleted over 
time; the increase in size observed for D, E and F after the expected initial decrease may 
be explained in terms of agglomeration that is consequent to the complete degradation 
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of the nanoparticles (Figure 3.27); considering the high concentration of the enzyme, it is 
possible that depleted NPs plays a significant role in this process. The esterase enzyme 
degradation study showed that the degradation of nanoparticles is directly proportional 
to the amount of enzyme, which is in agreement with published data (182), and that the 
higher the enzyme concentration the faster the degradation. 
 
 
Figure 3.27: Enzyme degradation of PECA-Dex100G4 over time, for different enzymatic activity (A= 0 units; B= 120 
Units; C= 220 Units; D= 420 units; E=620 units; F=1220 units). 
 
3.6. Conclusions  
In our hands, ethyl 2-cyano-3-ethoxyacrylate on its own could not be formulated into 
stable nanoparticles. The synthesis of PECA in phosphate buffer resulted in the formation 
of NPs that were characterised by poor yield, low zeta potential and high conductivity.  
PBCA-Dex100G4 NPs was prepared at an average size of 149.8 nm and zeta potential of -
47.8 mV. FTIR studies confirmed the presence of the cyanoacrylate group since the 
spectra exhibit the characteristic stretching vibrations of C=O (1743.88 cm−1), CN (2242 
cm-1) and C-O (1300 - 1000 cm-1). 
The dispersion of nanoparticles in water and its subsequent filtration through a PES 
membrane showed that the filtering process does not influence the DLS-determined 
characteristics of nanoparticles.  
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Alkylglyceryl dextran was successfully reacted with PLA through the zero-length grafting 
of PLA to alkylglyceryl dextran in the presence of DCC. As determined by 1H NMR, the 
degree of grafting of PLA to alkylglyceryl dextran was 163.9%. 
An esterase-induced degradation study of samples of PECADex100G4 showed that the 
higher the enzyme concentration the faster the degradation, as evidenced by the rate of 
the agglomeration process that accompanies nanoparticle depletion.  
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4 
4. Loading of nanoparticles with drugs, peptides and fluorophores 
 
The labelling of drug delivery vehicles with fluorescent dyes is rationalised in this work in 
terms of the capability to track the progress of the label through the host environment by 
means of the many fold array of fluorescence-detection technologies. To facilitate cell 
interaction studies, fluorophores, peptides and fluorescence drugs were loaded or tagged 
to the synthesised NPs. 
4.1. Actives and fluorophores 
 
Rhodamine B (Figure 4.1) is an organic dye that has been used traditionally as a tracer dye 
in water to determine the rate and direction of flow. Owing to its highly fluorescent 
nature and solubility in water, methanol and ethanol, Rhodamine B has found extensive 
use as a tracer molecule in biomedical research.  
 
Figure 4.1: Chemical structure of Rhodamine B 
 
Curcumin, found in rhizomes of curcuma longa or tumeric, is a low molecular weight 
diphenol-functionalised bis–α,β-unsaturated β-ketone that exists in equilibrium with its 
enol tautomer (183). Curcumin (structure in Figure 4.2) is soluble in both polar and non-
polar organic solvents. Although highly insoluble in water (11 ng/mL), it is soluble in 
alkaline or extremely acidic aqueous solvents; the pH-dependent solubility is assumed to 
be due to ionisation of the phenolic or enolic groups and/or due to degradation. This is 
Cl-
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witnessed by the solvent-dependent UV-vis absorption profile of Curcumin. Toluene 
solutions of the material fluorescence strongly, exhibiting maximum absorption at 418 
nm  (184). The main degradation products of Curcumin (185) are ferulic acid, 
feruloylmethane, vanilline and acetone. Curcumin is known to possess many therapeutic 
effects but is rapidly eliminated from systemic circulation (186).  
 
Figure 4.2: Chemical structure of Curcumin 
 
It has been suggested that the low bioavailability of Curcumin limits its capability to reach 
target tissues where it can exert its claimed pleiotropic effects. Hence, the covalent 
attachment of Curcumin to nanoparticles represents one approach towards overcoming 
this limitation.  
 
Because of its low aqueous solubility and its amphiphilic nature, the fluorescence 
intensity of Curcumin decreases with increasing water volume and also decreases as the 
acidity of its liquid host varies from neutral to extremely acidic or to basic (pH >8.0) (185). 
 
The absorption and fluorescence capacity of Curcumin may be used to both locate and 
quantify the molecular distribution in normal and tumour cells (187). The fluorescence of 
the molecule allows the visualisation of the distribution of Curcumin while UV absorption 
measurements provide a means for the quantification of this molecule within a specified 
sample size, rendering the molecule suitable for the assessment of the fate of Curcumin-
loaded nanoparticles for delivery through the BBB.  However, the determination of the 
fate of Curcumin in living tissues is limited by its amphiphilic nature and susceptibility to 
degradation: deprotonation of Curcumin effects spectral changes, both in terms of the 
extinction coefficient and in terms of the spectral profile (184) while degradation is 
manifested by  colour change.  Furthermore, the steady-state absorption and 
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fluorescence characteristics of Curcumin are sensitive to the immediate environment due 
to keto-enol isomerism. The loading of Curcumin amphiphilic NPs may therefore lead into 
structural changes that need to be taken into consideration in attempts to follow the fate 
of such nanoparticles. These potential complications are balanced by the capability of 
Curcumin-labelled nanoparticles to fluoresce in the blue laser channel, which renders 
those nanoparticles amenable to direct visualisation under the optical microscope. Also, 
the use of Curcumin fluorophores is complementary with the concomitant use of DAPI 
(4’6-diamino-2-phenyl indole) nuclear stain. Although the spectral characteristics of 
Curcumin are sensitive to solvent polarity  (188), the molecule displays an intense 
absorption band in the region 350-480 nm in all media of interest for this work.  
 
Figure 4.3: Chemical structure of Doxorubicin hydrochloride 
 
Doxorubicin (Figure 4.3) has been described as a very potent anti-cancer agent (189, 190) 
that has great potential for CNS chemotherapy but lacks the ability to cross the BBB 
because it is a substrate for the ATP-dependent efflux pump P-glycoprotein (P-gp) at the 
base of the BBB (191, 192). Prerequisite to the transport of Doxorubicin to the brain is the 
development of a suitable carrier that can cross or circumvent this barrier (193). Studies 
with P-gp suppressors (e.g. Cyclosporine A) have shown that significant amounts of 
Doxorubicin may be capable of penetrating the BBB following administration (191, 194). 
Also, PACA nanoparticles have been associated with the transport of Doxorubicin to the 
brain in significant amounts (91, 195). In another example, co-administration of 
Doxorubicin and Curcumin that had been loaded into PACA/chitosan nanoparticles has 
been suggested to increase the penetration of  Doxorubicin across the BBB (196). An 
additional benefit associated with the use of nanopolymeric PACA carriers is the claimed 
lowering of the cardiotoxicity of Doxorubicin, which is a known side effect that limits its 
.HCl
2
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use for therapeutic purposes (193, 197, 198). The change in the biodistribution profile of 
Doxorubicin NPs may be responsible for the relatively low cardiotoxicity of this agent.   
 
The ratio of copolymer to PECA in Doxorubicin nanoparticles is reported to influence the 
initial burst release of the drug from the nanoparticulate matrix, as is exemplified by the 
observation that a structure of PECA-PLGA in the 1:1 ratio exhibits reduced losses during 
the initial burst release of Doxorubicin (199). The burst release behaviour seen in this 
study may be due to the adopted ratio (1:6) of alkylglyceryl dextran to PECA. Notably, 
emulsifier-free PBCA loaded with Doxorubicin is reported to release its drug content very 
slowly, exhibiting a half-life of over 100 h in PBS (200).  
 
4.2 Methods and instrumentation 
Dialysis membrane (10000-MWCO) and PBS tablets were sourced from Sigma-Aldrich. 
Other equipment used included a: Perkin Elmer UV-Vis spectrophotometer, Grant water 
bath, Varian Cary Eclipse Fluorescence spectrophotometer, Falcon tubes (50 mL). The 
Perkin Elmer UV-Vis spectrophotometer was zeroed before use, with the wavelength set 
between 400-750nm. Samples were measure individually by placing the sample-
containing cuvette against that of the reference sample. A Varian Cary Eclipse 
spectrophotometer recorded fluorescence measurements after placing the sample-
containing cuvettes in the pre-zeroed sample reading chamber; the wavelength was set 
according to absorbance wavelength of the sample to be measured (excitation-emission) 
and data were processed using Cary Eclipse software. Mini-spin Eppendorf centrifuge. 
 
4.2.1. Loading of PECA-Dex, PECA-Dex100G4 and PECA-Dex100G8 NPs with Rhodamine B 
Rhodamine B solution (10 µl, 10 µg/µl) was added to a stirred suspension of PECA-Dex, 
PECA-Dex100G4 and PECA-Dex100G8 nanoparticles each (1 mL, 20 mg/mL) and stirring 
was continued for 3h at room temperature. After this time, the nanoparticles where 
separated by centrifugation (18000 g) and re-suspended in deionised water (5 mL) 
characterised by DLS (Figure 4.6). 
  
For the preparation of Polysorbate 80-coated nanoparticles, Polysorbate 80 (100 µl, 10% 
w/v) was added into the stirred suspension of PECA-Dex100 nanoparticles (tagged with 
Rhodamine B) to a final concentration of 1% (w/v) and stirring was continued for a further 
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30min. The particles were separated by centrifugation using the Eppendorf centrifuge 
(12200 rpm, 30 min) and re-dispersed following rinsing with deionised water and re-
suspension in deionised water (5mL) under sonication (10 min) and characterised with 
DLS (Table 4.1); the NTA fluorescing video record is placed in (Appendix 5). 
 
Monitoring the release of Rhodamine B 
PECA-dex, PECA-Dex100G4 and PECA-Dex100G8 nanoparticulate samples (2 mg) that had 
been loaded with Rhodamine B were each dispersed in PBS (10 mL, pH 7.4), and 
sonicated for 10 min before 1.5 mL of each solution was introduced into an 1.5 mL 
Eppendorf tube and incubated in a water bath (Grant thermostat temperature shaker,  
thermostatted at 37°C). Samples were removed sequentially at specified time intervals 
and centrifuged (12200 rpm, 15 min). To a specified volume of the supernatant (1 mL) 
was added to PBS (2 mL) and the absorbance was recorded over the UV range 650 nm to 
450 nm using a Elmer Perkin instrument; the variation in the intensity of the absorption 
maximum (564.76 nm) was monitored at specified time intervals. Since the release of 
Rhodamine B from nanoparticles was found to be very limited, this study was 
discontinued. 
 
4.2.2 PECA-Dex100G4 and PLA-Dex100G8PECA Nanoparticle-loading with Curcumin: the 
EtOH/H2O (1:1) method 
Curcumin (0.1 mg) was loaded onto PECA-Dex100G4 NPs and PLA-Dex100G8PECA NPs 
(100 mg) by stirring (overnight, room temperature) nanoparticles in ethanol-water (1:1 
v/v).  After this time, the samples were spun at 12200 rpm for 15 min using the mini-spin 
Eppendorf and the absorbance of the supernatants (1 mL aliquot to which 2 mL of DMSO 
had been added) were taken to determine the degree of loading. Concentration was 
determined using the equation of the calibration curve of Curcumin (Appendix 12). 
4.2.2.1 Determination of Curcumin content of PECA-Dex100G4 NPs and PLA-Dex100G8-
PECA NPs 
Freeze-dried nanoparticles (20 mg) of PECA-Dex100G4 and PLA-Dex100G8-PECA that had 
been loaded with Curcumin were each dissolved in DMSO (3 mL) and their absorbance 
were measured to allow the determination of the concentration of released Curcumin, 
which corresponds with that loaded onto the specified weight of nanoparticles. Again, 
loading was determined with reference to the standard plot of Curcumin in DMSO. 
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4.2.2.2 Loading of Curcumin into PECA-Dex100G4 nanoparticles: cross linking with acetic 
acid and TPP (Tripolyphosphate) 
The loading  of PECA-Dex100G4 NPs with Curcumin was conducted according to the 
method of Rejinold et al. (201) in which acetic acid and Tripolyphosphate (TPP) were 
employed to promote entrapment to the nanoparticles. A release study was conducted in 
which a portion (0.008 g) of the pellet was dispersed in PBS (10 mL) before being 
distributed into 9 Eppendorf tubes that were subsequently incubated at 37oC in a Grant 
water bath. Aliquots were withdrawn at specified time periods and each sample was spun 
for 5 min at 5000rpm; the method was not suitable because the released Curcumin was 
either sticking to the container or washed off during the process of supernatant removal.  
 
4.2.2.3 Loading and release of Doxorubicin hydrochloride from PECA-Dex6G4 NPs and 
PECA-Dex6G8 NPs by nanoprecipitation-solvent evaporation. 
Doxorubicin was loaded by nanoprecipitation using acetone as the organic solvent for 
ECA.  
Preparation of the NPs was by the monomer polymerisation method. ECA (150 µl) in 
acetone (25 mL) was gradually added to a stirring mixture of Dex6G4 or Dex6G8 (25 mg) 
in water (25 mL, 18.2mΩ) followed by Doxorubicin hydrochloride (2 mg) in acetone 
(concentration 2 mg/mL). The reaction mixture was allowed to stir overnight (room 
temperature) and the colloid that formed was separated by centrifugation at 40000 rpm 
for 30min. The amount of unloaded Doxorubicin hydrochloride in the supernatant was 
determined fluorimetrically. The pellet was dispersed in deionised water (10 mL) and 
after sonication (10 min) an aliquot (5 mL) of each sample was extracted and used for the 
release study. To this end, the aliquot (5 mL) of either PECA-Dex6G4-Dox or PECA-
Dex6G8-Dox was placed in a dialysis membrane bag and immersed in 50 mL capacity 
falcon tubes containing PBS (20 mL). The calculated amount of the free Doxorubicin 
hydrochloride equivalent contained in the nanoparticles was used as control. The samples 
were incubated in water bath (37°C) at an oscillating speed of 100 rpm. At specified time 
intervals, an aliquot (1 mL) of each sample was withdrawn and replaced with fresh media. 
Fluorescence intensity was measured using a Varian Cary Fluorescence 
spectrophotometer (Excitation and Emission wavelengths respectively at 480 nm and 590 
nm) and the amount of drug released at each time point was quantified by comparison 
against the Doxorubicin hydrochloride calibration curve (Appendix 14). 
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4.2.4 The preparation of PECA-Dex100G4-Dox 
Method: The preparation of PECA-Dex100G4-Dox was by the anionic emulsion 
polymerisation method, which is widely employed for the formulation of cyanoacrylate 
monomers into nanoparticles. ECA (100 µl) was gradually added to Dex100G4 (100 mg) in 
water (50 mL; 18.2 mΩ, pH 2.5) containing Doxorubicin hydrochloride (1.5 mg) and 
allowed to stir at room temperature for 4 h before neutralisation with aqueous NaOH (1 
N). The colloid that formed was filltered through P3 sintered glass. An aliquot of specified 
volume was taken and subjected to centrifugation (40000 rpm, 30 min). The pellet was 
dispersed in water (10 mL, 18 mΩ) and sonicated and thereafter characterised by DLS. 
Drug loading was calculated by subtraction following the determination of the drug 
content of the supernatant by UV-Vis measurements (400 nm-750 nm; Doxorubicin 
exhibits its absorbance maximum at 480nm). The Doxorubicin loading effeciency was 
determined to be 68.7%. 
4.2.5 Loading of Doxorubicin hydrochloride to PECA-Dex6G16 NPs 
The monomer polymerisation method via nanoprecipitation by solvent evaporation was 
used. To a flask (stirring) containing Dex6G16 (100 mg) and Doxorubicin (1.4 mg) in 
deionised water (100 mL) was added gradually and in sequence a solution of ECA (ethyl 2-
cyanoacrylate; 600 µl) in acetone (100 mL). Stirring was continued overnight (room 
temperature), after which time the mixture was spun (40000 rpm, 30 min; XL-90 Beckman 
Ultracentrifuge) and the pellet was dispersed in deionised water, sonicated (10 min) and 
freeze dried. 
4.2.6 Determination of EGFP enhanced green fluorescence protein (EGFP) 
PECA-Dex100G8-EGFP NPs were dispersed (1573 µg/mL) in PBS (pH7.4) and diluted to 
specified concentrations before the measurement of absorbance at each dilution to 
determine the concentration of EGFP through comparison with a BSA calibration curve 
(Appendix 15). 
4.2.7 Tagging of PECA-Dex100G8 with MIA 
The tagging of MIA to NPs was accomplished according to a published procedure (202). To 
a dispersion of PECA-Dex100G8 NPs (ca. 20 mg) in ethanolic sodium borate buffer (5 mL) 
was added under sonication/vortexing a solution of MIA (20 mg) in ethanol (0.2 mL); a UV 
lamp facilitated the detection of MIA (Figure 4.4; the MIA excitation and emission 
wavelengths are at 350nm and 445nm respectively).The mixture was dialysed (72 hr) and 
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freeze dried. Nanoparticle size was determined (DLS and Nanosight). MIA attachment to 
NPs was assessed further through visualisation by confocal microscopy (Appendix 9). 
 
Figure 4.4: MIA reaction with PECA-Dex100G8 
 
Purification of MIA-tagged nanoparticles with Sephadex 
Column chromatography (Sephadex 50 medium) was used in an effort to increase the 
purity of MIA-tagged NPs. After packing, the column was washed repeatedly with water 
(18.2 mΩ), (the eluent) before the sample was introduced. Fractions were collected in 
6mL aliquots. The second and third fractions were identified as those containing the 
fluorophore-tagged NPs, with the second fraction containing the highest proportion. 
Further fractions (up to nine 6mL aliquots) did not contain any fluorophore, as indicated 
with aid of a UV lamp.  
3
3
R=  H or
EtOH
pH 8.5
Borate buffer
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4.2.8 Tagging of MIA to PECA-Dex6G16 NPs and loading of Curcumin 
Method: PECA-Dex6G16 NPs (200 mg) was dispersed in sodium borate/ethanol (1:1; 
40mL) before being added to MIA (100 mg) in ethanol (20 mL). After sonication, the 
mixture was shaken in Bio-Rad (2h, room temperature) before purification by dialysis (72 
h). To the dialysed product was added Curcumin (1 mg) in acetone (2 mL) and stirring was 
continued for 3h (room temperature). After filtering (P3 sintered glass), the 
determination of Curcumin and MIA content in MIA-Curcumin-tagged nanoparticles was 
carried out by utilising the dual wavelength capability of the fluorimeter (Cary Eclipse, 
Varian Fluorescence Spectrophotometer). The excitation-emission wavelength of 
Curcumin was set at 420nm-480nm and that of MIA was set at 350nm-445nm. 
4.2.9 Tagging of Tetramethyl Rhodamine-5-carbonyl azide (TMRCA) to PECA-Dex6G12 
nanoparticles 
Method: PECA-Dex6G12 nanoparticles (50 mg) that had been dispersed in anhydrous 
toluene (20 mL) and mixed with TMRCA (0.6 mg) were allowed to stir at 80°C for 5h under 
an atmosphere of nitrogen (Figure 4.5) (203-205). After this time, the mixture was placed 
in a dialysis-membrane vessel (3500MWCO) and first dialysed against DMF (HPLC grade, 
Fisher) for 72 h before further dialysis against double-distilled water for 4 days. The 
aqueous-medium-derived Tetramethyl Rhodamine-nanoparticles were freeze dried. 
 
4.2.10 Evaluation of Evans blue retentive capacity 
To evaluate the retentive capacity of the nanoparticles for the dye, after loading Evans 
Blue to PECA-Dex6G4 NPs, the colloidal mixture that formed was centrifuged twice and 
after each centrifugation cycle, the absorbance of supernatant was measured. After the 
second centrifugation, the degree of loading was evaluated at 0.016% and the 
entrapment efficiency at 2.034%. An attempt to load Evans blue into PECA-Dex6G12 
nanoparticles yielded similar results; the calibration curve for Evans blue is appended 
(Appendix 16). 
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Figure 4.5: Covalent linkage of Tetramethyl Rhodamine to PECA-Dex6G12 nanoparticles 
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4.3 Results and discussion  
4.3.1 Rhodamine 
4.3.1.1 Rhodamine B loading into nanoparticles 
The size distribution of nanoparticles tagged with Rhodamine B coated with Polysorbate 
80 was within the range 400-500nm and exhibited low zeta potential (see example for 
Rhodamine B-loaded PECA-Dex100 NPs in Table 4.1). The size distribution of NPs tagged 
with Rhodamine B alone were within the size range 300 nm to 500 nm (Figure 4.6).  
Table 4.1:  Size, PDI and zeta potential of Rhodamine B-loaded, Polysorbate 80-coated PECA-Dex100 NPs 
parameter value 
Size (Z average) /nm 402.9±3.70 
PDI 0.35±0.012 
Zeta potential /mV -18.0±0.1 
  
 
 
Figure 4.6: Size of Rhodamine B-loaded nanoparticles prepared from PECA-Dex, PECA-Dex100G4 and PECA-Dex100G8 
(n=3) 
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4.3.2 Curcumin  
4.3.2.1 PECA-dex100G4 and PLA-dex100G8PECA Nanoparticle-loading with Curcumin: the 
EtOH/H2O (1:1) method 
In accord with expectation due to the very low solubility of Curcumin in water, Curcumin 
loading into nanoparticles was highly efficient (Table 4.2). 
Table 4.2: The absorbance and concentration of Curcumin in the supernatant ( EtOH:H2O), (1:1) from the loading of 
NPs. 
Sample Absorbance  Concentration  (µg/µl) 
PLA-Dex100G8-PECA-
Curcumin 
0.47308 0.00285 
PECA-Dex100G4-
Curcumin 
0.52779 0.00319  
 
4.3.2.2 Determination of Curcumin content of PECA-Dex100G4 Nps and PLA-Dex100G8-
PECA NPs 
Freeze-dried nanoparticles of PECA-Dex100G4-Curcumin NPs and PLA-Dex100G8-PECA-
Curcumin were evaluated for their Curcumin content (Table 4.3).  
Table 4.3: concentration of Curcumin content of dissolved Curcumin loaded NPs 
Sample Absorbance  Concentration 
(µg/µl) 
PLA-Dex100G8-PECA 
Curcumin 
0.64525 0.00392  
PECA-Dex1004G4 
Curcumin 
0.45075 0.00271  
 
4.3.3. Doxorubicin 
4.3.3.1 The preparation of PECA-Dex100G4-Dox 
The preparation of PECA-Dex100G4-Dox by the anionic emulsion polymerisation method 
yielded nanoparticles of low PDI and high zeta potential (Table 4.4). 
 
Table 4.4: Size, PDI and zeta potential of PECA-Dex100G4-Dox nanoparticles  
 
 
sample Size  PDI Zeta potential 
PECA-
Dex100G4-Dox 
281.0±6.7 nm 0.153±0.022 -35.7±2.7 mV 
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4.3.3.2 PECA-Dex6G16-Doxorubicin (PECA-Dex6G16-Dox) nanoparticles  
To assess the effects of purity on size, PDI and zeta potential, the characterisation of 
PECA-Dex6G16-Dox was carried out by DLS both before (as prepared) and after 
centrifugation (by resuspending the pellet and sonicating for 10 min). As compared with 
their as-prepared congeners, the purified NPs exhibit smaller size, lower PDI and higher 
zeta potential (Table 4.5), all of which highlight the importance of the purification step.  
 
Table 4.5: Size, zeta potential and PDI characterisation of Doxorubicin-PECA-Dex16 (Dox-PD16) nanoparticles (DLS) 
Sample  Size (nm) PDI Zeta Potential (mV) 
Before centrifugation  268.2±2.9 0.540±0.021 -26.2±0.5 
Dispersed pellet 254.0±4.6 0.389±0.047 -39.4±3.3 
 
 
4.3.3.3 Loading and release of Doxorubicin hydrochloride from PECA-Dex6G4 NPs and 
PECA-Dex6G8 NPs by nanoprecipitation-solvent evaporation 
The chain length of the Dex6G4 or Dex6G8 used as copolymer in the formation of 
nanoparticles of PECA-alkylglyceryl dextran that were loaded with Doxorubicin 
hydrochloride appears to affect loading capacity. Dex6G4, which has a shorter chain 
length as compared with Dex6G8, had a smaller amount of Doxorubicin hydrochloride 
loaded to its nanoparticulate formulation (PECA-Dex6G4) than Dex6G8 (PECA-Dex6G8). 
The more hydrophobic nature of Dex6G8 could have promoted the adsoption of the 
Doxorubicin hydrochloride [Doxorubicin base is hydrophobic whereas its  HCl salt is water 
soluble (206)]. The drug is assummed to be entrapped into PECA-Dex6G8 NPs in its 
hydrophilic Doxorubicin.HCl form, which probably enables efficient diffusion from the 
nanosphere matrix. Of the two nanoparticulates investigated, those of PECA-Dex6G8 NPs, 
which are associated with the higher loading capacity for Doxorubicin.HCl, were seen to 
exhibit the faster rate of release of this active. 
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Figure 4.7: Cumulative release profile of Doxorubicin from Doxorubicin HCl, PECA-Dex6G4 and PECA-Dex6G8 
(n=3±SD).  
 
The freeze dried nanoparticles drug content (Table 4.6) was determined by dissolving the 
NP-drug in DMSO  and the values were determined from the calibration curve (presented 
in Appendix 14). Samples of nanoparticles that had been subjected to freeze drying, 
contained drastically reduced amounts of entrapped drug relative to those that had not 
been subjected to a freeze drying protocol. This was particularly pronounced with PECA-
Dex100G4 NPs. The release of the Doxorubicin content of PECA-Dex6G8 or PECA-Dex6G4 
nanoparticles is influenced by polymer-chain hydrophilicity, which in turn is influenced by 
the liquid environment and by the amount of loaded drug that is retained in the 
nanoparticle matrix. The complex binding and releasing mechanisms are yet to be 
deconvoluted (207). 
 
Doxorubicin release from PECA-Dex6G8-Dox nanoparticles was very fast (similar to that of 
the free Doxorubicin from the dialysis-membrane bag; Figure 4.7). PECA-Dex6G4-Dox 
nanoparticles had about 40% of their drug content released within about 8 h from the 
start of the release study, which also saw about 95% of the drug released from PECA-
Dex6G8 nanoparticles within the same timescale (Figure 4.7). The release profile (Figure 
4.7) of Doxorubicin from the nanoparticulate matrix, especially that of PECA-Dex6G8-Dox, 
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suggested that almost all loaded Doxorubicin had been released within few hours. It is 
possible that Doxorubicin release from these nanoparticles may have been better 
controlled if structures containing different ratios of the constitutional polymers had 
been used, or by the use of Doxorubicin in its free base form. The release profiles 
demonstrated that the nanoparticles exhibited limited affinity for the drug at the 
temperature and pH of the adopted experimental protocol. 
Table 4.6: Percentage Doxorubicin loading to the nanoparticles (loading efficiency) 
sample % drug loaded  
PECA-Dex100G4 45.8% 
PECA-Dex100G8 58.3% 
 
4.3.3.4 Loading of both Doxorubicin and Curcumin into PECA-Dex100G12nanoparticles: 
The monomer polymerisation method provided the means for the loading of PECA-
Dex100G12 nanoparticles with equal proportions of Curcumin and Doxorubicin (208). 
Since for both molecules OH functionalities may become involved in the initiation of the 
polymerisation of ECA, the formulation cannot be regarded as a mere combination of 
Doxorubicin and Curcumin but rather as a molecular complex of these actives with the 
nanoparticles. Accordingly, release studies involving this nanoparticulate complex have 
shown that Doxorubicin is released from the complex at a faster rate than Curcumin. In 
the absence of detailed spectroscopic characterisation data the relative contributions of 
the binding forces that operate between the individual components of the complex 
cannot be deconvoluted.  However, the observed release patterns suggest that these 
nanoparticles may be amenable to employment for therapeutic purposes; Table 4.7 
summarises the DLS characterisation data of Doxorubicin-Curcumin nanoparticles. 
 
 
Table 4.7: Size, PDI and zeta potential of PECA-Dex6G12 nanoparticles loaded with Doxorubicin-Curcumin. 
 Size (nm) PDI Zeta potential (mV) 
 DLS NTA Mode   
PECA-
Dex100G12-
Dox-Cur 
211.4±0.1 152±66 120 0.249±0.022 -30.40±0.40 
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4.3.3.5 PECA-Dex100G12-Dox TGA and DSC results  
TGA performed under an atmosphere of nitrogen indicated that the main degradation 
step for PECA-Dex100G12-Dox is characterised by a mass loss of 91.4% (Figure 4.8), with a 
maximum rate of mass loss at 192.0 °C. The second step of the same thermogram is 
associated with a mass loss of 7.7% and exhibits a peak mass loss rate at 327.5 °C. 
Exposed to a synthetic air atmosphere the sample exhibited an additional mass loss of 
1.1%. 
 
Figure 4.8: TGA plots from PECA-Dex100G12-Dox nanoparticles. 
 
In (Figure 4.9) the first heating curve (blue curve) of this sample, there is observed a glass 
transition at 52.4 °C (midpoint) which is accompanied by a change in specific heat 
capacity of 0.059 J/g*K. Immediately after the glass transition, a broad endothermic event 
is observed which is assumed to be associated with the onset of evaporation or with the 
oxidative degradation of a components of the sample. The second heating curve (green 
curve) confirms the glass transition at 52.3 °C and enumerates the change in specific heat 
capacity at 0.041 J/g*K. Notably, the endothermic event did not occur during the second 
heating cycle, which is indicative of a possible relaxation effect in the polymer structure. 
 
 
Loading of nanoparticles with drugs peptide and fluorophores  
108 
 
 
Figure 4.9: DSC of PECA-Dex100G12–Doxorubicin nanoparticles. 
 
Since the extraction of Doxorubicin-free base with methanol and triethylamine has been 
shown to be an effective means of increasing Doxorubicin entrapment in the PECA-
DexnGm nanoparticles (199), it is  likely that the use of Doxorubicin as its hydrochloride 
salt would have affected the extent of entrapment to PECA-DexnGm nanoparticles. The 
interactions between PACA and Doxorubicin have been indicated to involve the 
establishment of hydrogen bonds between the ammonium N-H function and the cyano 
group, while the cohesion of PACA nanoparticles have been indicated by the same 
technique to be due to the combined effects of electrostatic forces, H-bonds and dipolar 
interactions (163). 
 
4.3.4 Other fluorescent markers and model drugs 
4.3.4.1 Enhanced green fluorescence protein (EGFP) determination in NPs 
Determination of EGFP at various concentrations of PECA-Dex100G8-EGFP NPs 
EGFP loading was studied over a range of concentrations of nanoparticles that had been 
dispersed in PBS. This was to confirm whether the fluorescence protein has been loaded 
unto the nanoparticles. The various concentrations of the NPs-loaded EGFP confirmed the 
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presence of the fluorescence marker in the NPs (Table 4.8). The nanoparticles were 
further analysed with SEM. SEM image of PECA-Dex100G8-EGFP loaded nanoparticles is 
appended in (Appendix 10) 
 
Table 4.8: Determination of concentrations of EGFP in PECA-Dex100G8-EGFP NPs 
Initial Conc. of NPs  (µg/mL) Absorbance (nm) Conc. of EGFP  
(µg/mL)* 
100 0.0558 1.294 
200 0.0770 13.760 
300 0.1084 32.240 
400 0.3335 164.558 
500 0.3481 173.240 
 
4.3.4.2 N-methyl-isatoic anhydride (MIA) 
Dispersion of freeze dried MIA-NPs in a range of media demonstrated the medium-
influenced variation in the size of nanoparticles (Table 4.9).  
 
Table 4.9: The effect of different liquid media on the size distribution of NPs of PECA-Dex100G8 that had been tagged 
with MIA (DLS) 
Liquid medium  Z-av.d (nm) PDI 
water 141.4±1.0 0.241±0.006 
NaCl (10mmol) 133.2±1.6 0.224±0.009 
PBS (7.4) 226.0±5.3 0.467±0.011 
PBS (filtered 0.2µm) 134.6±0.4 0.221±0.007 
 
In an experiment designed to establish the optimum method of co-loading MIA and 
Curcumin, it was observed that the tagging of MIA before loading the sample with 
Curcumin was more efficient than that involving loading with Curcumin before tagging 
with MIA (Table 4.10); DLS results of sizes and zeta potentials are presented in (Table 
4.11). 
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Table 4.10: Fluorescence intensity of MIA-Curcumin nanoparticles 
sample Tagged with MIA before 
loading with Curcumin 
Loaded with Curcumin 
before tagging with MIA 
Fluorescence 
intensity (Curcumin) 
56.9538 20.5744 
Fluorescence 
intensity(MIA) 
507.3941 547.0530 
 
Table 4.11: DLS analysis of MIA-Curcumin NPs 
Loaded with Curcumin before 
tagging with MIA 
 Tagged with MIA before loading 
with Curcumin 
Z-Av (nm) 634.5±16.1  Z-av (nm) 430.1±8.0 
PDI 0.159±0.023  PDI 0.248±0.009 
Zeta potential 
(mV) 
-27.6±0.1  Zeta potential 
(mV) 
-23.0±0.5 
 
 
4.3.4.3 Tetramethyl Rhodamine-5-carbonylazide 
The synthesis of Tetramethyl Rhodamine-nanoparticles by covalent bond formation 
involved reaction between the hydroxyl group of constituent macromolecules and the 
isocyanate group formed from the acyl azide functionality of TMRCA on heating at 80°C. 
The conjugation of these molecules was evidenced by NTA, and by the difference 
between the fluorescence intensities of the blank and Tetramethyl Rhodamine 
nanoparticles dissolved in DMSO as measured with Microplate Reader.  Proton NMR 
(205) was used to determine the molar ratio of the attached Tetramethyl Rhodamine to 
the nanoparticles by comparing the signal intensity or the peak area of its methyl proton 
to the anomeric proton of the pyranose ring of the dextran or, the methylene protons (or 
methyl protons) of  the alkyl glyceryl group attaching to the dextran. 
Evidence for the conjugation of Tetramethyl Rhodamine to the nanoparticles was 
obtained by considering the difference in fluorescence intensities of nanoparticles with 
reference to a blank sample, which had been dissolved in DMSO and measured 
(Microplate Reader) at the respective excitation and emission wavelengths of 544 nm and 
590 nm; fluorescence intensities obtained were 21902 for Tetramethyl Rhodamine tagged 
nanoparticles and 1952 for empty nanoparticles. The linking of Tetramethyl Rhodamine 
to the nanoparticles was further evidenced with NTA, in that fluorescing Tetramethyl 
Loading of nanoparticles with drugs peptide and fluorophores  
111 
 
Rhodamine nanoparticles could be observed when the filter was shut. The sizes of tagged 
nanoparticles, as measured by DLS and NTA, are presented in (Table 4.12). Since the size 
distribution of nanoparticles was high, as reflected by the associated PDI, the separation 
of nanoparticles to narrower size samples was attempted by filtration.   
 
 
Table 4.12: The size and PDI of PECA-Dex6G12-TMRCA nanoparticles (n=1) 
 DLS NTA(nm) 
 Size (nm) PDI Size  Mode  
NP-TMRCA 879.6±42.8 0.525±0.030 735±264 752 
 
4.3.4.4 Evans Blue 
Loading of PECA-Dex100G4 NPs with Evans blue 
Evans blue dye (structure in Figure 4.10) was loaded into the nanoparticles by means of 
the monomer polymerisation method. The degree of loading and the efficiency of 
entrapment were determined by measuring the Evans blue content of the supernatant. 
The system exhibited a poor loading efficiency and an associated low degree of loading. 
Evans blue is a negatively charged dye; it is possible that the negative zeta potential of 
PECA-DexnGm nanoparticles is responsible for the poor affinity of this dye for these 
nanoparticles. 
 
Figure 4.10: Chemical structure of Evans blue 
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4.4 Conclusions 
Rhodamine B was successfully loaded into the nanoparticles but since the release of 
Rhodamine B from nanoparticles was poor this study was discontinued. 
 
To promote the entrapment of Curcumin into nanoparticles, the loading of PECA-
Dex100G4 NPs with Curcumin was carried out in the presence of acetic acid and TPP. 
However, inherent to this method was the inefficient study of the release profile. 
 
The study of the release of Doxorubicin hydrochloride indicated that nanoparticles of 
PECA-Dex6G4 NPs can sustain the release of Doxorubicin hydrochloride more efficiently 
than those formulated from longer chain homologues (e.g. PECA-Dex6G8 NPs). 
 
Towards the optimisation of methods of tagging MIA to nanoparticles, it was observed 
that the tagging of MIA prior to loading with Curcumin was preferable to the tagging of 
MIA after Curcumin had been loaded to the nanoparticles. 
 
EGFP was successfully loaded into the nanoparticles as confirmed by absorbance 
measurements at specified concentrations. 
 
The synthesis of Tetramethyl Rhodamine-containing nanoparticles by covalent bond 
formation was achieved through reaction between the hydroxyl group of constituent 
macromolecules and the isocyanate group formed from the acyl azide functionality of 
TMRCA. The successful tagging of TMRCA to the nanoparticles was indicated by NTA and 
by the difference in fluorescence intensities of nanoparticles with reference to those of 
the blank as determined using the microplate reader. 
 
 Evans blue had very low affinity for the nanoparticles as evidence by the ease with which 
the dye washed away from their nanoparticulate hosts. 
  
In vitro studies  
113 
 
5 
5. In vitro studies - Cytotoxicity  
 
The cytotoxicity of nanoparticulate formulations was assessed by measuring the viability 
of mouse brain endothelial cells (bend3) following incubation with selected 
nanoformulations. 
5.1 Methods and instrumentation 
The cytotoxicity evaluation protocol involved the following materials and equipment: 
incubator (37°C, 5% CO2), Plate reader PolarStar Optima (BMG Labtech) (570nm 
Absorbance filter), 96-well plate (Greiner bio-one) Fisher, inverted microscope, 
haemocytometer, pipettes (1 mL, 100 µl, 50 µl, 20 µl), class II safety cabinet, sterile 
pipette tips, sterile pipette (10mL, 3mL) disposable, sterile 0.4 µm polyethersulfone (PES) 
filter, electric pipette (Fisher), T25 culture flask (Fisher), centrifuge, alkyl cyanoacrylate-
alkylglyceryl dextran NPs, alkylglyceryl dextrans, MTT (3-(4,5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide), DMEM (media), trypan blue, Triton-X100, PBS, Tryple 
Express, mouse-brain endothelial cells (bend3), DMEM (500 mL), L-Glutamine (5 mL), 
Sodium pyruvate (5 mL), 2-mercaptoethanol (0.5 mL), NEAA (5 mL), FBS (50mL), 
Pen/Strep (5 mL).  
The cytotoxicity study was conducted by means of the MTT (3-(4, 5-dimethylthiazolyl-2)-
2, 5-diphenyltetrazolium bromide)  assay (209, 210): MTT metabolism is known to show a 
good correlation between cell viability and conversion of MTT tetrazolium salt (yellow) to 
MTT formazan (purple) since only metabolic active cells have the capacity to effect the 
conversion of this salt to its purple metabolite.  
Various alkyl cyanoacrylate-alkylglyceryl dextrans NPs and alkylglyceryl dextrans were 
assessed at 1 mg/mL concentration. 
To assess the concentrations of nanoparticles that induce cytotoxicity to bend3 cells, a 
dose-response study employing a MTT assay were conducted for PECA-Dex100G4 NPs 
(1:1), PECA-Dex100G4 NPs (1:6) and PBCA-Dex100G4 NPs samples at four specified 
concentrations (10 μg/mL, 25 μg/mL, 50 μg/mL and 100 μg/mL). 
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MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay protocol 
The MTT working solution was prepared by allowing a solution of MTT in DMEM (5 
mg/mL; kept in the dark at 2-8°C until needed) to reach 37°C and a steady state 
concentration of 5% CO2 before dilution (1:5) with DMEM. Bend3 cells (20,000) were 
seeded (in triplicate) into each of a 96 well plate containing 200 µl of normal media 
(DMEM containing 10% fetal bovine serum, FBS) and incubated for 24h. After this time, in 
each well were added 20 µl of each nanoformulation and of alkylglyceryl dextran 
formulations dispersed in PBS at specified concentrations prior to incubation for 24h at 
37°C (5% CO2). After this time, to each well was added MTT working solution (50 µl) and 
the mixture was incubated for 2h at 37°C (5% CO2). The media was then removed from 
each well, replaced with 100 µl of DMSO and this mixture was agitated gently until the 
formazan crystals had dissolved. Each plate was inserted into the plate reader and the 
absorbance was read at 570 nm. The viability of cells was calculated (Equation 5.1) as 
percentage relative to PBS (negative control); Triton-X100 provided the positive control.  
 
100*
.
.
%..Re
controlA
testA
viabilitycelllative     (eq. 5.1) 
 
5.2 Results and Discussion 
 
Tested against bend3 cells at a relatively high concentration of 1 mg/mL (MTT assay), 
PECA and PECA-alkylglyceryl dextran nanoparticles exhibited significant cytotoxicity 
(p<0.05) as compared with the PBS control (Figure 5.1). 
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Figure 5.1: Relative toxicity of PECA and PECA-alkylglyceryl dextran nanoparticles (1mg/mL; p<0.05, n=3) 
 
 
Figure 5.2: Relative cytotoxicity of alkylglyceryl dextrans (1mg/mL; p<0.05, n=3) 
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To account for these results, alkylglyceryl dextrans were also evaluated using the same 
assay, and the results (Figure 5.2) exhibited variable behaviour in that Dex100G4 was 
cytotoxic relative to the PBS control (p<0.05) while Dex100G16, Dex6G4 and Dex6G16 did 
not display any statistically significant  differences at the p<0.05 level with reference to 
the same control. It appears that a decrease in the molecular weight of dextran reduces 
cytotoxicity, though the degree of substitution with alkylgyceryl chains is clearly another 
contributing factor. 
 
 
Figure 5.3:  Relative viability as a function of dose response  of alkyl cyanoacrylate NPs against bend3 cells, each 
incubated at specified concentrations  (10 μg/mL, 25 μg/mL  50 μg/mL  100 μg/mL)  for 24 h; MTT assay; Triton –X100 
and media blank (n =3; ±SD; Triton-X100 positive control). 
 
To identify a range of safe concentrations, a dose response study has been carried out; 
the apparent toxicity induced by PECA was also compared to that of poly(butyl 
cyanoacrylate), by testing nanoparticles that were prepared from the same materials but 
where ECA was replaced by BCA.  We found that PBCA-Dex100G4 NPs at concentrations 
of up to 50  µg/mL were well tolerated by bend3 cells (Figure 5.3, Table 5.1) while NPs of 
PECA-Dex100G4 (1:1) and PECA-Dex100G4 (1:6) began to exhibit toxic effects at 
concentrations >25 µg/mL. 
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Table 5.1: Cytotoxicity dose response of alkyl cyanoacrylate-alkylglyceryl dextran NPs against bEND3 cells  
Sample  viability (Abs) percentage 
viability 
SD 
Media 1.8002 100.0000 0.0294 
PBCA-10 1.6036◊ 89.0808 0.2972 
PBCA-25 1.5912◊ 88.3901 0.2988 
PBCA-50 1.4338◊ 79.6504 0.3314 
PBCA-100 0.5609* 31.1613 0.0096 
PECA(1:1)10 1.5958◊ 88.6475 0.1781 
PECA(1:1)25 1.3793◊ 76.6211 0.2434 
PECA(1:1)50 0.4315* 23.9714 0.2047 
PECA(1:1)100 0.3808* 21.1569 0.0213 
PECA(1:6)10 1.4633◊ 81.2891 0.2183 
PECA(1:6)25 1.3477◊ 74.8657 0.1566 
PECA(1:6)50 0.3850* 21.3902 0.0421 
PECA(1:6)100 0.3507* 19.4811 0.0292 
0.1%T-X100Media 0.2697 14.9853 0.0295 
0.1%T-X100(water) 0.2046 11.3654 0.0030 
1%T-X100(media) 0.2716 15.0890 0.0045 
*significant difference (P<0.05) compared to media; 
 ◊ significant difference (P<0.05) compared to 0.1% TritonX100 
Legend:  
PBCA-10 =PBCA-Dex100G4 NPs at dose of 10 µg/mL 
PBCA-25 =PBCA-Dex100G4 NPs at dose of 25 µg/mL 
PBCA-50 =PBCA-Dex100G4 NPs at dose of 50 µg/mL 
PBCA-100 =PBCA-Dex100G4 NPs at dose of 100 µg/mL 
PECA(1:1)10=PECA-Dex100G4,(equal ratio of PECA:Dex100G4) at dose of 10 µg/mL 
PECA(1:1)25=PECA-Dex100G4,(equal ratio of PECA:Dex100G4) at dose of 25 µg/mL 
PECA(1:1)50=PECA-Dex100G4,(equal ratio of PECA:Dex100G4) at dose of 50 µg/mL 
PECA(1:1)100=PECA-Dex100G4,(equal ratio of PECA:Dex100G4) at dose of 100 µg/mL 
PECA(1:6)10=PECA-Dex100G4,( ratio 1:6 of Dex100G4:PECA) at dose of 10 µg/mL 
PECA(1:6)25=PECA-Dex100G4,( ratio 1:6 of Dex100G4:PECA) at dose of 25 µg/mL 
PECA(1:6)50=PECA-Dex100G4,( ratio 1:6 of Dex100G4:PECA) at dose of 50 µg/mL 
PECA(1:6)100=PECA-Dex100G4,( ratio 1:6 of Dex100G4:PECA) at dose of 100 µg/mL 
 
Literature reports indicate that, when tested against a L929 fibroblast cell culture, ethyl 
and isobutyl cyanoacrylate-derived nanoparticles were found to be more toxic than the 
methyl derivative, which showed intermediate toxicity, while isohexyl cyanoacrylate was 
the least cytotoxic of the materials tested (81). A further study involving cyanoacrylate 
nanoparticles (PMCA,PECA,PBCA and PIBCA) and mouse peritoneal macrophages showed 
identical cellular damage for all tested cyanoacrylates particles (211), indicating that 
contrary to earlier reports, chain length influences toxicity. Nemati et al. have reported 
that the toxicity of cyanoacrylates on P388 cells is time dependent and that the rate and 
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amount of uptake is determined by the cell types against which the evaluation is 
conducted (212).  
The cytotoxicity of poly(cyanoacrylate) nanoparticles seems to be more complex than the 
direct contributions of each of the released degradation products, stimulation of 
inflammation mediators and cell adhesion (107, 213):  concentration and time appear to 
play an important role. For example, literature indicates that PBCA nanospheres did not 
induce any cytotoxicity at a concentration of 75 µg/mL while membrane damage was 
observed at a concentration of 150 µg/mL (107). This in turn indicates that PBCA may 
become cytotoxic at a specified concentration >75 µg/mL. In another example, 
poly(isobutyl cyanoacrylate) nanospheres at 100 µg/mL exhibited no cell toxicity within 
the 7 h timescale but showed notable mortality beyond 24 h (81). Other reports on the 
cytotoxicity of cyanoacrylates are available in the literature, but those are limited to the  
concentration level of  0.1 mg/mL (214). 
Although retro-Knoevenagel to poly(acrylic acid) and the corresponding alcohol is 
assumed to be the major degradation pathway of cyanoacrylate polymers, the cellular 
cytotoxicity of cyanoacrylate polymers has been shown to be directly related to the 
release of formaldehyde (215), which is produced though a minor pathway during the 
degradation of PACA (214). The rate of degradation is  primarily determined by the length 
of the side chain, with shorter chain homologues degrading more readily (presumably due 
to the steric hindrance effects exerted by the longer-chain materials; (216).  Due to its 
relative high propensity to adhere to cells (81, 107) PECA would be expected to exhibit 
higher toxicity than its shorter-chain homologue PMCA.  Contrary to expectation, when 
tested against fibroblasts, PMCA was found to be more toxic than PECA (214). A study of 
the cytotoxicity of PBCA and POCA (10 µg/mL) against human foreskin fibroblasts showed 
that the former material is more toxic (217).  
As compared with the PBS control, the PECA and PECA-derived nanoparticles evaluated in 
this study at concentration of (1 mg/mL) exhibited marked toxic effects against all cells 
tested (bend.3) (Figure 5.1). Complementary dose-response experiments that included 
PBCA-derived nanoparticles have demonstrated that the respective toxicities of PBCA-
Dex100G4 NPs, and PECA-Dex100G4 (both 1:1 and 1:6 ratio samples) nanoparticles are 
notable at the 100 μg/mL and the 50 μg/mL levels, respectively (Figure 5.3 and Table 5.1). 
With reference to the PBS control, Dex100G4 appeared significantly more toxic but no 
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significant difference in toxicity could be identified (P<0.05) with Dex100G16, Dex6G16 or 
Dex6G4 (Figure 5.2). 
Consistent with the findings of Wiegand et al. who reported the molecular-weight-
dependent toxic effects of chitosan on human keratinocyte cell lines (218), the 
percentage viabilities (214) determined for alkylglyceryl dextran samples of different 
molecular weights imply that similar molecular-weight-dependent effects operate with 
the latter class of molecules. Notably however, tested against CT-26 cells, dextran derived 
micelles did not appear to exhibit a significant molecular weight-related effect (219). 
 
5.3. Conclusions 
Since complementary studies have indicated that the chain length of PACAs influences 
their rate of degradation, it is assumed that there is a relationship between chain length 
and toxicity: the shorter the chain, the faster the degradation and the more toxic the 
parent structure. It is notable however that the toxicity of degradation products of PACA 
nanoparticle is reported, through the evaluation of data from clinical trials, not to induce 
any adverse effects of therapeutic significance (220). The molecular weight of native 
dextran and the degree of substitution with alkylglyceryl chains also appear to influence 
the cytotoxicity of the nanoparticulate formulations tested. 
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6. General Conclusions and suggestions for further work 
The delivery of therapeutic agents to the brain is often limited by the BBB. Research 
findings have indicated that this barrier may be overcome by the use of nanoparticulate 
drug delivery vehicles which incorporate the therapeutic molecule that is not capable of 
crossing the BBB. To achieve this goal, it is essential that nanocarriers that do not alter 
the integrity of the BBB are developed. 
This study designed and evaluated one such class of drug-carrying polymeric 
nanoparticles. To this end, dextran derivatives have been prepared through attachment 
of alkylglycerol of systematically varied chain length to the dextran core. These 
macromolecular structures were then combined with a widely used class of 
biocompatible moieties, the alkyl cyanoacrylates, to formulate nanoparticles. 
Alkylglycerols of systematically varied chain lengths were utilised to generate alkylglyceryl 
derivatives of two native dextrans with average molecular weights of 6 kD and 100 kD. 
These alkylglyceryl dextrans were characterised by MALDI-TOF MS, TGA, GPC, FTIR and 
NMR. The degree of substitution of each of the synthesised alkyl glyceryl dextrans, as 
determined using 1H-NMR spectroscopy, ranged between 30% and 200%. It was found 
that the longer the chain length of the progenitor alkylglycerol the lower the 
hydrophilicity of the alkylglyceryl dextran. GPC results demonstrated that the 
polydispersity index of alkylglyceryl dextrans was lower than that of the precursor 
dextran irrespective of average molecular weight (6 kDa or 100 kDa).  
In the chemical attachment of alkylglycerol to dextran the carbon at position 2 was seen 
to be regioselectively favoured, as is consistent with its expected higher reactivity. The 
synthesised alkylglyceryl dextrans were readily amenable to formulation into 
nanoparticles through combination with alkyl cyanoacrylates (ethyl or butyl); the 
techniques of nanoprecipitation and emulsion polymerisation were both usefully 
employed for this purpose. Nanoparticles were characterised by DLS, NTA, elemental 
(CHN) analysis, NMR, FTIR, MALDI-TOF MS, SEM, DSC and TGA. Elemental analysis 
calculations determined that the ratio of alkylglyceryl dextran to alkyl cyanoacrylate in 
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the formulated nanoparticles was in the respective, formulation-dependent, range of 3-
19% and 80-95%; this was in agreement with NMR data. 
The sizes of nanoparticles were of the order of 100-500 nm. Studies involving the 
systematic variation of the alkylglyceryl chain length indicated that there is no direct 
relationship between chain length and nanoparticle size. Notably, nanoparticles that had 
been prepared from alkylglyceryl dextrans exhibited consistently higher negative zeta 
potentials than their congeners that had been formulated from native dextrans. 
Autotitration experiments revealed that empty NPs exhibit decreasing zeta potentials 
with decreasing pH. The average sizes of nanoparticles appeared relatively stable across 
the pH range considered, while the sizes decreased with decrease in pH for some of the 
tested nanoparticles. 
The nanoparticles were amenable to tagging with fluorophores and to loading with a 
range of model drugs (MIA, EGFP, Curcumin, Doxorubicin, Evans blue, TMRCA). 
Experiments involving nanoparticles that had been loaded with Curcumin demonstrated 
that the longer the alkylglyceryl chain length the smaller the size of nanoparticles. 
Studies of the release of loaded Evans blue have shown the rapid release of this agent 
from the nanoparticulate matrix, presumably due to the incompatibility in the surface 
charges of the negatively charged Evans blue and the negative-zeta-potential 
nanoparticles. The release of Doxorubicin or that of Curcumin from their nanoparticulate 
host was notably slower than that observed with Evans blue. 
Evaluated for cytotoxicity against bend3 cells, nanoparticles exhibited dose-dependent 
toxicity profiles: PBCA-Dex100G4 NPs were found to be more biocompatible than PECA-
Dex100G4 NPs.  
Integral to the future development of the technology towards clinical applications is an in 
vitro study that evaluates nanoparticles for their capability to permeate modelled BBB 
structures. 
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APPENDIX 4                                                
SEM image of PECA-Dex100G4 
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APPENDIX 5                                 
Video snapshot of PECA-NP loaded Rhodamine B and coated with Polysorbate 80 
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APPENDIX 6                                              
 Thermograms of modified dextrans 
 
Figure A6.1: TGA results of Dex6G8 
 
 
 
Figure A6.2: TGA results of Dex6G12 
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Figure A6.3: TGA results of Dex6G14 
 
 
Figure A6.4: TGA results of Dex6G16 
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Figure A6.5: TGA results of Dex100 
 
 
Figure A6.6: TGA results of Dex100G4 
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Figure A6.7: TGA results of Dex100G8 
 
 
Figure A6.8: TGA results of Dex100G12 
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Figure A6.9: TGA results of Dex100G14 
 
 
Figure A6.10: TGA results of Dex100G16 
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APPENDIX 7                                    
 
MALDI TOF spectra of modified dextrans  
 
Figure A7.1 MALDI- TOF Spectrum of Dex100G4 
 
 
Figure A7.2: MALDI TOF spectrum of Dex6G8 
O
O
OH
OH
O
O
O
OH
C
7
H
11
O
6
191.0556 Da
C
7
H
15
O
2
131.1072 Da
Molecular Formula  = C
14
H
26
O
8  
146.0 
130.1 
O
O
OH
OH
O
O
O
OH
C
7
H
11
O
6
191.0556 Da
C
11
H
23
O
2
187.1698 Da
 
56.2. 
Appendices 
145 
 
 
 
 
Figure A7.3: MALDI TOF Spectrum of Dex100G8 
 
 
Figure A7.4 MALDI TOF spectrum ofDex6G12 
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Figure A7.5 MALDI TOF spectrum of Dex100G12  
 
 
Figure A7.6 MALDI TOF spectrum of Dex6G14 
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Figure A7.7 MALDI TOF spectrum of Dex100G14 
 
 
Figure A7.8 MALDI TOF Spectrum of Dex6G16  
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Figure A7.9 MALDI TOF spectrum of Dex100G16 
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APPENDIX 8        
 
MALDI TOF spectra of nanoparticles 
 
Figure A8.1 MALDI TOF spectrum of PECADex100G4 
 
 
Figure A8.2: MALDI TOF spectrum of PECADex6G8 
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Figure A8.3: MALDI TOF spectrum of PECADex100G8 
 
Figure A8.4: MALDI TOF spectrum of PECADex100G12 
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Figure A8.5: MALDI TOF spectrum of PECADex6G16 
 
Figure A8.6: MALDI TOF spectrum of PECADex100G16 
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APPENDIX 9   
 
Confocal microscopy image of  PECA-Dex100G8 tagged with MIA in PBS 
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APPENDIX 10    
 
 
SEM image of PECA-Dex100G8 EGFP nanoparticles 
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APPENDIX 11          
 
 
Equations used to calculate the polymer mass composition from the results of elemental 
analysis  
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APPENDIX 12                       
 
 
Calibration curves used for the determination of Curcumin 
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APPENDIX 13  
 
SEM images of native dextran and Dex100G4 
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APPENDIX 14  
 
Calibration curves for Doxorubicin 
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APPENDIX 15  
 
Calibration curve for BSA 
 
 
Appendices 
159 
 
 
 
APPENDIX 16  
 
Calibration curve for Evans blue 
 
 
Calibration curve of Evans blue 
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